



- (51) International Patent Classification:  
A61K 9/127 (2006.01) A61K 48/00 (2006.01)
- (21) International Application Number:  
PCT/US2016/047406
- (22) International Filing Date:  
17 August 2016 (17.08.2016)
- (25) Filing Language:  
English
- (26) Publication Language:  
English
- (30) Priority Data:  
62/206,121 17 August 2015 (17.08.2015) US
- (71) Applicant: MODERNATX, INC. [US/US]; 320 Bent Street, Cambridge, MA 02141 (US).
- (72) Inventor: SMITH, Michael, H.; 25 Whiting Way, Needham, MA 02492 (US).
- (74) Agent: LOCKHART, Helen, C.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report (Art. 21(3))

WO 2017/031232 A1

(54) Title: METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS




FIG. 1

(57) Abstract: Methods for preparing particles and related compositions are provided. In some embodiments, the particles include at least one polynucleotide (e.g., mRNA), and in certain embodiments, the particles may include at least one ionizable molecule (e.g., a lipid). A method for preparing a suspension including the particles may comprise one or more filtration steps. In some such embodiments, prior to or during filtration, one or more properties of the particles (e.g., surface charge) and/or one or more properties of the suspension (e.g., pH) may be altered. In some embodiments, altering one or more properties of the particles and/or suspension may improve yield, improve a characteristic of the resulting composition, and/or prevent or reduce certain problems, such as fouling during the filtration process.

## **METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS**

### **RELATED APPLICATIONS**

5           This application claims priority under 35 U.S.C. § 119(e) to United States Provisional Application Serial No. 62/206,121, filed August 17, 2015, the contents of which are incorporated herein by reference in its entirety for all purposes.

### **FIELD OF INVENTION**

10           The present embodiments relate generally to methods for preparing particles comprising polynucleotides and related compositions.

### **BACKGROUND**

15           It is of great interest in the fields of therapeutics, diagnostics, reagents, and for biological assays to be able control protein expression. Most methods rely upon regulation at the transcriptional level (e.g., from DNA to mRNA), but not at the translational level (e.g., from mRNA to protein). Although attempts have been made to control protein expression on the translational level, the low levels of translation, the immunogenicity of the molecules, and other delivery issues have hampered the  
20           development of mRNA as a therapeutic.

          There remains a need in the art to be able to design, synthesize and deliver a nucleic acid, e.g., a ribonucleic acid (RNA) such as a messenger RNA (mRNA) encoding a peptide or polypeptide of interest inside a cell, whether *in vitro*, *in vivo*, *in-situ*, or *ex vivo*, such as to effect physiologic outcomes which are beneficial to the cell, tissue or  
25           organ and ultimately to an organism.

### **SUMMARY OF THE INVENTION**

          Methods for preparing particles comprising polynucleotides and related compositions associated therewith are provided. In some embodiments, the preparation  
30           involves one or more filtration steps. The subject matter of this application involves, in some cases, interrelated products, alternative solutions to a particular problem, and/or a plurality of different uses of structures and compositions.

          In some embodiments, a series of methods are provided. In one embodiment, a method comprises changing a pH of a suspension comprising particles comprising

mRNA and an ionizable molecule from a first pH to a second pH, wherein the second pH is greater than a pKa of the ionizable molecule, and filtering the suspension to produce a filtered suspension comprising at least a portion of the particles, wherein a coefficient of variation of a cross-sectional dimension of the particles in the filtered suspension is less than or equal to about 20%.

In another embodiment, a method comprises changing a pH of a suspension comprising particles comprising mRNA and an ionizable molecule from a first pH to a second pH, wherein the second pH is greater than a pKa of the ionizable molecule, and forming a composition comprising at least a portion of the particles, wherein a coefficient of variation of a cross-sectional dimension of the particles in the composition is less than or equal to about 20%.

In another embodiment, a method comprises changing an average zeta potential of a plurality of particles comprising mRNA in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential, and filtering the suspension to produce a filtered suspension comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the filtered suspension is greater than or equal to about 50% and less than or equal to about 99%.

In another embodiment, a method comprises changing an average zeta potential of a plurality of particles comprising mRNA in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential, and forming a composition comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the composition is greater than or equal to about 50% and less than or equal to about 99%.

In another embodiment, a method comprises changing an average zeta potential of a plurality of particles comprising polynucleotides having greater than or equal to 50 nucleotides in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential, and filtering the suspension to produce a filtered suspension comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the filtered suspension is greater than or equal to about 50% and less than or equal to about 99%.

In another embodiment, a method comprises changing an average zeta potential of a plurality of particles comprising polynucleotides having greater than or equal to 50

nucleotides in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential, and forming a composition comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the composition is greater than or equal to about 50% and less than or equal to about 99%.

In another embodiment, a method of filtering comprises filtering a suspension comprising particles comprising a polynucleotide and an ionizable molecule having a pKa less than the pH of the suspension, wherein the filtration step comprises a concentration step and a diafiltration step, and wherein the permeate flux throughout the diafiltration step is greater than or equal to about 20 L/m<sup>2</sup>h when the transmembrane pressure is between about 1 psi and about 20 psi.

In another set of embodiments, compositions are provided. In one embodiment, a composition comprises a plurality of particles comprising mRNA, wherein an average cross-sectional dimension of the particles in the composition is less than or equal to about 150 nm, a coefficient of variation of a cross-sectional dimension of the particles in the composition is less than or equal to about 20%, and a weight percentage of mRNA in the particles is greater than or equal to about 50% and less than or equal to about 99%.

Other advantages and novel features of the present invention will become apparent from the following detailed description of various non-limiting embodiments of the invention when considered in conjunction with the accompanying figures. In cases where the present specification and a document incorporated by reference include conflicting and/or inconsistent disclosure, the present specification shall control. If two or more documents incorporated by reference include conflicting and/or inconsistent disclosure with respect to each other, then the document having the later effective date shall control.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each

embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention. In the figures:

FIG. 1 is a process flow diagram showing a method of forming particles comprising polynucleotides, according to certain embodiments;

5 FIG. 2 is a schematic diagram of a graph showing the magnitude of charge of particles versus pH, according to certain embodiments; and

FIG. 3 is a schematic diagram of particles described herein, according to certain embodiments;

10 FIG. 4 shows a graph of percent encapsulation versus residence time in an acidic buffer, according to certain embodiments;

FIG. 5 shows a graph of zeta potential versus pH for various particles, according to certain embodiments;

FIG. 6A shows a graph of permeate flux versus time for suspensions with various pHs, according to certain embodiments;

15 FIG. 6B shows a graph of permeate flux at different stages of tangential flow filtration for suspensions with various pHs, according to certain embodiments;

FIG. 7A shows the average particle size during various stages of tangential flow filtration and after a sterile filtration for suspensions with various pHs, according to certain embodiments;

20 FIG. 7B shows the percent polydispersity for particles in suspensions with various pHs during various stages of tangential flow filtration and after a sterile filtration, according to certain embodiments.

### DETAILED DESCRIPTION

25 Methods for preparing particles and related compositions are provided. In some embodiments, the particles include at least one polynucleotide (e.g., mRNA), and in certain embodiments, the particles may include at least one ionizable molecule (e.g., a lipid). A method for preparing a suspension including the particles may comprise one or more filtration steps. In some such embodiments, prior to or during filtration, one or  
30 more properties of the particles (e.g., surface charge) and/or one or more properties of the suspension (e.g., pH) may be altered. For instance, the average surface charge and/or zeta potential of the particles may be altered by changing the pH of a suspension containing the particles to a pH that is greater than or equal to the pKa of one or more

components included in the particles (e.g., an ionizable molecule). In some such embodiments, the magnitude of the average surface charge and/or zeta potential of the particles after changing the pH is greater than the magnitude prior to changing the pH. In some embodiments, altering one or more properties of the particles and/or suspension may improve yield, improve a characteristic of the resulting composition, and/or prevent or reduce certain problems, such as fouling during the filtration process. For instance, the methods described herein may result in a composition including particles having less variations with respect to one or more therapeutically-relevant parameters (e.g., cross-sectional dimension, weight percentage of polynucleotide) compared to a composition formed by certain existing methods.

A non-limiting process flow diagram of a method for preparing a suspension including particles comprising polynucleotides (e.g., mRNA) is shown illustratively in FIG. 1. In some embodiments, a method for preparing a suspension may include forming steps, an altering step, and/or one or more filtration steps, amongst others. For instance, a first solution comprising polynucleotides (e.g., mRNA) and a second solution comprising one or more components (e.g., ionizable molecule, sterol molecule) may be combined in step 22 to form a mixture 25 comprising the polynucleotides and component(s). After the combining step, the mixture may undergo an incubation step 27. In some embodiments, the incubation step may comprise one or more dilution steps. In some instances, a dilution step may be used to alter the concentration of one or more component (e.g., organic solvent) in the mixture. Over time, the polynucleotides and component(s) may spontaneously form, and/or be induced to form, a suspension containing particles 30. For example, the composition of the first and/or second solutions (e.g., solvents) may be selected to induce co-precipitation of the polynucleotides (e.g., mRNA) and one or more components (e.g., ionizable molecule) during an incubation step 27 to form particles 30.

In some embodiments, the incubation time, timing of dilution, ratio of the first and second solutions, and/or another condition (e.g., concentration of polynucleotides, pH) may be controlled to influence one or more properties of the resulting particles. For instance, the incubation time (i.e., the time allowed for the first and second solutions to mix or combine before a subsequent process step) may be controlled to influence the weight percentage of polynucleotide (e.g., mRNA) in the particles. In certain embodiments, the dilution timing may be controlled to tailor the average cross-sectional

dimension of the particles. For instance, particle growth may be quenched after a certain period of time via a dilution. Methods for controlling the incubation time and other features are described in more detail below.

As shown illustratively in FIG. 1, the method may also involve altering one or more properties of the particles in a step 32 to form altered particles 35, as described in more detail below. Subsequently, the altered particles may be filtered during a filtering step 37 to form a filtered suspension containing particles 40.

Referring back to the step of forming the suspension containing particles 30, the particles may be formed by any suitable method. In some embodiments, the particle formation steps may be performed in a fluidic device, such as a microfluidic device. For instance, a first channel may contain a first solution and a second channel may contain a second solution. In some such embodiments, the combination step may be performed using a device comprising a T junction that merges the first and second channels, as described in U.S. Provisional Patent Application Serial No. 62/040,989, filed August 22, 2014, entitled "Lipid Nanoparticles for Nucleic Acid Molecules and Uses Thereof," which is incorporated by reference in its entirety.

Other methods of forming the particles described herein are also possible. For instance, in embodiments in which the particles are liposomes, methods of forming liposomes can be used as described in more detail below.

In some embodiments, the particles may be formed such that one or more of the components (e.g., initially contained in the second solution) at least partially (e.g., partially, completely) encapsulates at least a portion of the polynucleotides (e.g., initially contained in the first solution). For instance, in some embodiments, the particles comprise a component in the form of an ionizable molecule (e.g., an ionizable lipid). The ionizable molecules may encapsulate (e.g., partially, completely) at least a portion of the polynucleotides. In some cases, substantially all of the polynucleotides in the particles are encapsulated by the ionizable molecules. For example, the particles may include an outer layer of the ionizable molecules with the polynucleotides positioned in the interior of the particles. In other embodiments, a portion of the polynucleotides may be exposed at the surface of the particles, but another portion of the polynucleotides may be encapsulated within the interior of the particles. In certain embodiments, the particles comprise two or more components (e.g., an ionizable lipid, at least one other lipid, and/or at least one sterol) that together encapsulate (e.g., partially, completely) at least a portion

of the polynucleotides. In some cases, substantially all of the polynucleotides in the particles are encapsulated by the two or more components. For instance, the polynucleotides may be encapsulated (e.g., partially, completely) by an ionizable lipid, at least one other lipid, and/or at least one sterol. A particle comprising polynucleotides and one or more lipid molecules may be referred to as a lipid particle.

In some embodiments, particles 30 may be formed such that one or more components of the particles may serve to at least partially (e.g., partially, completely) shield and/or neutralize the charge of the polynucleotides. In such cases, the magnitude of charge at the surface of the particles and/or the zeta potential of the particles may be relatively small. For instance, in embodiments in which the particles comprise an ionizable molecule, at least a portion of the charge of the polynucleotides may be shielded by the ionizable molecules. In some such embodiments, the ionizable molecule may be oppositely charged with respect to the overall charge of the polynucleotides.

In some embodiments, such particles having a relatively low surface charge may be difficult to filter (e.g., based on size) under certain conditions. For instance, passing the particles through a porous substrate to separate particles based on size and/or to remove certain contaminants may result in fouling of the porous substrate. In some such cases, fouling may limit the efficacy of separation, prevent the formation of a filtered suspension comprising particles that have a relatively narrow distribution in cross-sectional dimension, and/or allow a significant amount of certain contaminants to remain. In certain applications, such a variance in the cross-sectional dimension and/or concentration of certain contaminants may limit the utility of the particles. In some instances, the filtered suspension may have to undergo further complex, time-consuming, and/or costly all of y purification steps prior to utilization.

It has been discovered within the context of certain embodiments described herein that altering one or more properties of the particles and/or suspension prior to and/or during filtration, as indicated by step 32 in FIG. 1, can reduce and/or eliminate certain problems associated with filtration, such as fouling. In some embodiments, the altering step may increase the magnitude of the average surface charge and/or zeta potential of the particles. This change can increase the repulsion forces between the particles during filtration. Increasing the repulsion forces can reduce or prevent the agglomeration of substances (e.g., particles, components, and/or polynucleotides) at, near, or within the pores of the porous substrate, thereby reducing the amount of fouling



of the porous substrate. In some instances, the altering step may allow efficacious sterile filtering of the suspension. In some instances, the altering step may allow efficacious tangential flow filtration, including ultrafiltration and diafiltration.

5 Additionally or alternatively, in some embodiments, altering one or more properties of the particles and/or suspension prior to and/or during filtration may allow the formation of particles 40 having a desirable property. For example, the particles may have a relatively small coefficient of variation (e.g., less than or equal to about 20%) in a cross-section dimension, a relatively high weight percentage of encapsulated polynucleotides (e.g., greater than or equal to about 85% of encapsulated/bound  
10 polynucleotide vs. free polynucleotide), amongst other features, as described in more detail herein.

It should be appreciated that the steps shown in FIG. 1 can vary. For example, although FIG. 1 shows the altering step 32 as being performed before filtration step 37, in some embodiments the altering step may occur during the filtration step as described  
15 herein. In other embodiments, the filtered suspension containing particles 40 may be subjected to one or more further processing steps 39 (e.g., altering tonicity, altering pH, altering stabilizer concentration, altering ionic strength) to obtain a suspension containing particles 45.

As described herein, a method for preparing a suspension including particles  
20 comprising polynucleotides (e.g., mRNA) may involve an altering step. In some embodiments in which the particles include an ionizable molecule, the altering step may involve changing a pH of the suspension from a first pH to a second pH that is greater than a pKa of the ionizable molecule. For instance, the pH of the suspension prior to an altering step (and/or during or after formation of the particles) may be less than a pKa of  
25 the ionizable molecule. The pH of the suspension may then be altered by adding a suitable base to increase the pH of the suspension to be greater than a pKa of the ionizable molecule.

In some embodiments, the pH of the suspension prior to an altering step (and/or during or after formation of the particles) may be less than or equal to about 6.5, less  
30 than or equal to about 6, less than or equal to about 5.8, less than or equal to about 5.5, less than or equal to about 5.2, less than or equal to about 5, less than or equal to about 4.8, or less than or equal to about 4.5. In some embodiments, the pH prior to the altering step (and/or during or after formation of the particles) may be greater than or equal to

about 3, greater than or equal to about 3.2, greater than or equal to about 3.5, greater than or equal to about 3.8, greater than or equal to about 4.0, greater than or equal to about 4.2, greater than or equal to about 4.5, or greater than or equal to about 5.0.

Combinations of the above referenced ranges are also possible (e.g., greater than or equal to about 3 and less than or equal to about 6). Other ranges are also possible. In some  
5 embodiments in which the pH is greater than the pKa prior to the altering step and/or during particle formation, one or more properties (e.g., weight percentage of polynucleotide, cross-sectional dimension, coefficient of variation in cross-sectional dimension) of the particle may be adversely affected or may make particle formation  
10 infeasible.

In some embodiments, the pH of the suspension after the altering step (e.g., a pH altering step) may be greater than or equal to about 6, greater than or equal to about 6.2, greater than or equal to about 6.4, greater than or equal to about 6.5, greater than or equal to about 6.6, greater than or equal to about 6.8, greater than or equal to  
15 about 7, greater than or equal to about 7.2, greater than or equal to about 7.4, greater than or equal to about 7.4, greater than or equal to about 7.5, greater than or equal to about 7.6, greater than or equal to about 7.8, or greater than or equal to about 8. In some embodiments, the pH after the altering step may be less than or equal to about 9.0, less than or equal to about 8.8, greater than or equal to about 8.6, less than or equal to about  
20 8.5, greater than or equal to about 8.4, less than or equal to about 8.2, less than or equal to about 8.0, less than or equal to about 7.8, greater than or equal to about 7.6, or less than or equal to about 7.5. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 6.5 and less than or equal to about 8, greater than or equal to 7 and less than or equal to about 8). Other ranges are also possible.

In some embodiments, the pH of the suspension after the altering step (e.g., a pH altering step) may be within a certain range or may have a certain value greater than the pKa of one or more components (e.g., ionizable molecule) in the particles. In certain  
25 embodiments, the pH of the suspension after the altering step may be greater than or equal to about 0.2 pH units, greater than or equal to about 0.4 pH units, greater than or equal to about 0.5 pH units, greater than or equal to about 0.6 pH units, greater than or equal to about 0.8 pH units, greater than or equal to about 1 pH unit, greater than or equal to about 1.2 pH units, greater than or equal to about 1.4 pH units, or greater than or equal to about 1.5 pH units greater than the pKa of one or more components (e.g.,  
30

ionizable molecule) in the particles. In some instances, the pH of the suspension after the altering step may be less than or equal to about 2.0 pH units, less than or equal to about 1.8 pH units, less than or equal to about 1.5 pH units, less than or equal to about 1.2 pH units, less than or equal to about 1.0 pH unit, or less than or equal to about 0.8 pH units greater than the pKa of one or more components (e.g., ionizable molecule) in the particles. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 0.5 pH units and less than or equal to about 2 pH units, greater than or equal to 1 pH unit and less than or equal to about 1.5 pH units). Other ranges are also possible. In some embodiments, the ionizable molecule is a cationic lipid such as 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). Other ionizable molecules are described herein.

In certain embodiments, the altering step may involve changing an average zeta potential of the particles from a first zeta potential to a second zeta potential that is greater than the magnitude of the first zeta potential.

In some embodiments, the average zeta potential of the particles prior to an altering step (and/or during or after formation of the particles) may be positive. In some such embodiments, the average zeta potential of the particles prior to an altering step (and/or during or after formation of the particles) may be greater than or equal to about +0.1 mV, greater than or equal to about +0.5 mV, greater than or equal to about +1.0 mV, greater than or equal to about +1.5 mV, greater than or equal to about +2.0 mV, greater than or equal to about +5.0 mV, greater than or equal to about +10.0 mV, greater than or equal to about +15.0 mV, greater than or equal to about +20.0 mV, or greater than or equal to about +25 mV. In some such cases, the average zeta potential of the particles prior to an altering step (and/or during or after formation of the particles) may be less than or equal to about +30 mV, less than or equal to about +25 mV, less than or equal to about +20 mV, less than or equal to about +15 mV, less than or equal to about +10 mV, less than or equal to about +5 mV, less than or equal to about +3 mV, or 0 mV. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to about +1.0 mV and less than or equal to about +30 mV).

In other embodiments, the average zeta potential of the particles prior to an altering step (and/or during or after formation of the particles) may be negative. In some

such embodiments, the average zeta potential of the particles may be greater than or equal to about -2 mV, greater than or equal to about -1.8 mV, greater than or equal to about -1.5 mV, greater than or equal to about -1.2 m, greater than or equal to about -1 mV, greater than or equal to about -0.8 mV, or greater than or equal to about -0.5 mV.

5 In some cases, the average zeta potential of the particles prior to an altering step (and/or during or after formation of the particles) may be 0 mV or less than or equal to 0.1 mV. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to about -2 mV and less than or equal to 0.1 mV).

In some embodiments, the average zeta potential of the particles after an altering  
10 step may be less than or equal to about -2 mV, less than or equal to about -3 mV, less than or equal to about -5 mV, less than or equal to about -8 mV, less than or equal to about -10 mV, less than or equal to about -12 mV, less than or equal to about -15 mV, greater than or equal to about -18 mV, less than or equal to about -20 mV, less than or equal to about -22 mV, less than or equal to about -25 mV, less than or equal to about -  
15 28 mV, less than or equal to about -30 mV, or less than or equal to about -35 mV. The average zeta potential of the particles after an altering step may be greater than or equal to about -40 mV, greater than or equal to about -38 mV, greater than or equal to about -35 mV, greater than or equal to about -30 mV, greater than or equal to about -28 mV, greater than or equal to about -25 mV, greater than or equal to about -22 mV, greater  
20 than or equal to about -20 mV, greater than or equal to about -18 mV, greater than or equal to about -15 mV, greater than or equal to about -12 mV, greater than or equal to about -10 mV, greater than or equal to about -8 mV. Combinations of the above referenced ranges are also possible (e.g., less than or equal to -1 mV and greater than or equal to about -10 mV). Other ranges are also possible.

25 In some embodiments, the average zeta potential of the particles may be negative after the altering step. In some such embodiments, the average zeta potential of the particles comprising an ionizable molecule and at least one polynucleotides may be less than the average zeta potential of essentially identical particle that do not comprise a polynucleotide. It should be understood that as used herein, when the zeta potential of  
30 particles are compared (e.g., less than, greater than), the comparison is based on the value of the zeta potential and not the magnitude. For instance, a zeta potential of -30 mV is less than a zeta potential of -1 mV.

In some instances, a change in pH of a suspension may cause a change in the magnitude and/or polarity of the surface charge, and accordingly the zeta potential, of the particles, as illustrated in FIG. 2. FIG. 2 illustratively shows the surface charge of particles in a suspension at a pH below the pKa of one or more components of the particles (e.g., an ionizable molecule) and at a pH above the pKa of one or more components of the particles. As illustrated in FIG. 2, the sign of the surface charge of the particles at a pH below the pKa may be opposite of the sign of the surface charge of the particles at a pH above the pKa. It should be understood that FIG. 2 is illustrative and that the sign of the surface charge of the particles need not be at a pH below the pKa need not be opposite of the sign of the surface charge of the particles at a pH above the pKa in all embodiments. In some embodiments, the average magnitude of the surface charge of the particles before the altering step may be greater than the magnitude the average magnitude of the surface charge of the particles after the altering step. In some such embodiments, the average magnitude of surface charge of the particles after the altering step may be greater than before the altering step. In certain embodiments, regardless of the average magnitude and/or polarity of the surface charge after the altering step, the altering step may serve to increase the repulsive force between particles.

Without being bound by theory, it is believed that the change in surface charge of the particles as a function of pH may be due, at least in part, to deprotonation of the ionizable lipid. For example, when the ionizable lipid is positively charged, at pH values less than the pKa, the positively charged ionizable lipid components bind negatively charged species on the surface and present an overall stoichiometric excess of positive charge. As the positive charge is diminished at pH values greater than the pKa, surface-accessible negatively charged groups (e.g., lipids, nucleotides) are no longer neutralized and can dominate the charge profile.

In some embodiments, and as shown illustratively in FIG. 3, after formation of a particle 50 and/or prior to an altering step, particle 50 may be arranged such that ionizable molecules 55 at least partially encapsulate polynucleotides 60. The ionizable molecule may comprise a charged portion (e.g., a nitrogen-containing functional group) that shields the charge of the polynucleotide, resulting in a relatively small charge at a surface 67 of the particle. Particle 50 may be present in a suspension, in some embodiments, prior to altering the pH of the suspension to a pH that is greater than the

pKa of the ionizable molecule. In some embodiments, altering the pH of the suspension to a pH that is greater than the pKa of the ionizable molecule may alter the charge state of the charged portion of the ionizable molecule. For example, the percentage of charged ionizable molecules (e.g., ionizable lipids) may be reduced for positively charged ionizable molecules. In some embodiments, the change in the charge state of the charged portion of the ionizable molecule may result in reorganization of the particle components to form an altered particle 70. For example, as shown in FIG. 3, reorganization may result in at least a portion of the polynucleotides being present on the surface of particle 70. The presence of polynucleotides on the surface of the particle may increase the magnitude of the surface charge. For instance, the polynucleotides on the surface may make the particles have a greater surface charge. In other embodiments, the change in the charge state of the charged portion of the ionizable molecule may not result in structural reorganization of the particle. In some such embodiments, as the pH is adjusted and the charge state of ionizable molecule is diminished, the balance shifts resulting in a change in sign for zeta potential. In some such cases, the change in the ionization of charged groups on the surface of the particles results in a change in zeta potential by a shift in counter ion solvation around the molecules in the particle.

It should be understood that FIG. 3 is non-limiting and other particle configurations are possible. For instance, in some embodiments the ionizable molecules in particle 50 may have a different configuration compared to their configuration in particle 70. In some cases, particles 50 and 70 are liposomes (i.e., liposomal particles). In some such cases, the particles may comprise a lipid bilayer surrounding an aqueous interior. In some embodiments, liposomes can be, but not limited to, a multilamellar vesicle (MLV) and may contain a series of concentric bilayers separated by narrow aqueous compartments or an unicellular vesicle.

In some cases, particles including certain components may be more prone to fouling during filtration compared to particles including other components. In certain embodiments, particles prone to fouling may have a relatively low or neutral surface charge (e.g., particle 50 of FIG. 3). Causing the particles to rearrange to have an overall greater surface charge (e.g., particle 70 of FIG. 3) may reduce fouling as described in more detail herein.

In some embodiments, a method described herein comprises certain particle formation steps. In some such embodiments, the formation steps may comprise a

combination step and/or an incubation step. The combination step may comprise mixing an aqueous solution comprising a buffer and polynucleotides (e.g., mRNA) (e.g., a first solution) with a solution comprising a solvent such as an organic solvent (e.g., an alcohol) and particle components (e.g., ionizable molecules, sterol) (e.g., a second solution). After the combination step, the suspension may be incubated to allow for particle formation. In some embodiments, one or more properties of the particles and/or resulting composition, such as weight percentage of polynucleotides (e.g., mRNA) in the particle, may be improved by tuning the incubation time. The incubation time may be measured from the time of combining the first and second solutions until the time of a subsequent process step (e.g., an alteration step). In some embodiments, the subsequent process step is altering the pH of the suspension to a pH greater than the pKa of a component (e.g., ionizable molecule) of the particles, such that the incubation time is measured from the time of combining the first and second solutions until the pH of the suspension is greater than the pKa a component of the particles.

An incubation time as described herein may vary. For instance, in some embodiments, the incubation time may be greater than or equal to about 3 minutes, greater than or equal to about 4 minutes, greater than or equal to about 5 minutes, greater than or equal to about 6 minutes, greater than or equal to about 8 minutes, greater than or equal to about 10 minutes, greater than or equal to about 12 minutes, or greater than or equal to about 15 minutes. In some embodiments, the incubation time may be less than or equal to about 30 minutes, less than or equal to about 20 minutes, less than or equal to about 18 minutes, less than or equal to about 15 minutes, less than or equal to about 12 minutes, less than or equal to about 10 minutes, less than or equal to about 8 minutes, or less than or equal to about 6 minutes. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 5 minutes and less than or equal to about 20 minutes). Other ranges are also possible.

In some embodiments, the incubation step may comprise one or more dilution steps (e.g., two dilution steps). In some embodiments, a dilution step may be used to alter the concentration of one or more components in the mixture (e.g., organic solvent). In some embodiments, the dilution step may facilitate particle formation. In certain embodiments, one or more dilution steps may adjust the pH of the mixture. In such embodiments, the pH of the mixture after the dilution step may be altered to be less than the pKa of one or more components (e.g., ionizable molecules) in the mixture.

In some embodiments, a dilution step may be used to slow down, limit, and/or quench particle growth. That is, in some embodiments, a dilution step may be used to control the average cross-sectional dimension of the particles. In certain embodiments, the incubation step may comprise two dilution steps. For instance, one dilution step may be used to change the concentration of a component in the mixture and another dilution step may be used to control (e.g., quench) particle growth.

As described herein, in some cases, an altering step (e.g., altering pH) may be performed. The altering step may be performed at any suitable time after one or more of the particle formation steps (e.g., a formation step, a combining step, an incubation step). For instance, in some embodiments, the time of an altering step may be greater than or equal to about 1 minute, greater than or equal to about 3 minutes, greater than or equal to about 5 minutes, greater than or equal to about 8 minutes, greater than or equal to about 10 minutes, greater than or equal to about 12 minutes, greater than or equal to about 15 minutes, greater than or equal to about 18 minutes, greater than or equal to about 20 minutes, or greater than or equal to about 25 minutes after one or more of the particle forming steps (e.g., a formation step, a combining step, an incubation step). In some embodiments, an altering step may be performed less than or equal to about 30 minute, less than or equal to about 28 minutes, less than or equal to about 25 minutes, less than or equal to about 22 minutes, less than or equal to about 20 minute, less than or equal to about 18 minutes, less than or equal to about 15 minutes, less than or equal to about 12 minutes, less than or equal to about 10 minutes, less than or equal to about 8 minutes, or less than or equal to about 6 minutes after one or more of the particle forming steps (e.g., a formation step, a combining step, an incubation step). Combinations of the above referenced ranges are also possible e.g., greater than or equal to 5 minutes and less than or equal to about 30 minutes).

In some embodiments, a method described herein may allow the particles to have a relatively high encapsulation efficiency of a component of the particle (e.g., a polynucleotide, sterol). For instance, in some embodiments, the encapsulation efficiency of a component may be greater than or equal to about 50%, greater than or equal to about 55%, greater than or equal to about 60%, greater than or equal to about 65%, greater than or equal to about 70%, greater than or equal to about 75%, greater than or equal to about 80%, greater than or equal to about 85%, greater than or equal to about 90%, greater than or equal to about 95%, or greater than or equal to about 99%. In some instances, the



encapsulation efficiency of a component may be less than or equal to about 100%, less than or equal to about 99%, less than or equal to about 95%, less than or equal to about 90%, less than or equal to about 85%, less than or equal to about 80%, less than or equal to about 75%, less than or equal to about 70%, less than or equal to about 65%, or less than or equal to about 60%. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 75% and less than or equal to about 100%). The encapsulation efficiency is determined by the percentage (e.g., by weight, mol) of the component in the particles compared to the initial amount of the component used prior to particle formation and purification. In embodiments in which more than one component is included in the particles, each component may independently have an encapsulation efficiency in one or more of the above-referenced ranges.

As noted above, a method described herein may comprise one or more filtration steps. In some embodiments, the one or more filtration steps may include tangential flow filtration (e.g., cross-flow filtration with a membrane), clarifying filtration, and/or sterile filtration (e.g., with a 0.2 micron filter). In some embodiments, the methods steps described herein may prevent or reduce fouling during tangential flow filtration and/or sterile filtration. Other filtration methods are also possible, as described in more detail herein.

In some embodiments, the filtration step (e.g., tangential flow filtration) may include one or more concentration filtration steps and one or more diafiltration (e.g., buffer exchange, wash) steps. For instance, the filtration step may include two or more concentration filtration steps and a diafiltration step. In some such cases, a concentration step may be performed before and after the diafiltration step. As used herein, the term “concentration filtration step” has its ordinary meaning in the art and refers to a filtration step in which the concentration of one or more components in the collected fraction is greater than the concentration of component(s) in the original feed. In some embodiments, the collected fraction may be the permeate, also referred to as the filtrate. In some embodiments, the collected fraction is the retentate, also referred to as the concentrate. In some embodiments, the concentration filtration may be ultrafiltration. As used herein, the term “diafiltration” has its ordinary meaning in the art and refers to a technique that uses a filter to remove, replace, or lower the concentration of one or more components in the feed (e.g., salts, solvent). In some embodiments, a filtration step may include a diafiltration step that involves passing a certain volume (e.g., diafiltration

volume) of a fluid through the filter and/or filtration system. As used herein, the term “diafiltration volume” or “diavolume” has its ordinary meaning in the art and may refer to the volume of retentate (e.g., total volume of reservoir plus the hold-up volume of tubing, filter, holder, etc.) at the start of diafiltration.

5           In some embodiments, multiple diafiltration volumes may be passed through the filter and/or filtration system during the filtration step. For instance, in some embodiments, greater than or equal to about one diafiltration volume, greater than or equal to about two diafiltration volumes, greater than or equal to about three diafiltration volumes, greater than or equal to about four diafiltration volumes, greater than or equal to about five diafiltration volumes, greater than or equal to about six diafiltration volumes, greater than or equal to about eight diafiltration volumes, greater than or equal to about ten diafiltration volumes, greater than or equal to about twelve diafiltration volumes, or greater than or equal to about fifteen diafiltration volumes may be used during a diafiltration step. In some instances, less than or equal to about twenty  
10 diafiltration volumes, less than or equal to about ten diafiltration volumes, less than or equal to about eight diafiltration volumes, less than or equal to about seven diafiltration volumes, less than or equal to about six diafiltration volumes, less than or equal to about five diafiltration volumes, less than or equal to about four diafiltration volumes, or less than or equal to about three diafiltration volumes may be used during a diafiltration step.  
15 Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to about two diafiltration volumes and less than or equal to about ten diafiltration volumes, greater than or equal to about five diafiltration volumes and less than or equal to about eight diafiltration volumes).

As described herein, the disclosed method(s) may result in a reduction of fouling during filtration. In some embodiments, the reduction in fouling during filtration may allow a relatively high permeate flux to be achieved and/or may allow a relatively high permeate flux to be maintained throughout the filtration step or at least a portion of the filtration step (e.g., during a concentration step and/or diafiltration step). As used herein, the term “permeate flux” has its ordinary meaning in the art and refers to the rate of  
25 sample flow through a given filter area per unit time.  
30

In some embodiments, the permeate flux during the filtration step and/or at least a portion of the filtration step (e.g., during concentration step(s) and/or a diafiltration step, e.g., after at least about 5 diafiltration volumes) at a transmembrane pressure of

between about 1 psi and about 20 psi (e.g., between about 10 psi and about 15 psi) may be greater than or equal to about 10 L/m<sup>2</sup>hr, greater than or equal to about 20 L/m<sup>2</sup>hr, greater than or equal to about 30 L/m<sup>2</sup>hr, greater than or equal to about 40 L/m<sup>2</sup>hr, greater than or equal to about 50 L/m<sup>2</sup>hr, greater than or equal to about 60 L/m<sup>2</sup>hr, 5 greater than or equal to about 70 L/m<sup>2</sup>hr, greater than or equal to about 80 L/m<sup>2</sup>hr, greater than or equal to about 90 L/m<sup>2</sup>hr, greater than or equal to about 100 L/m<sup>2</sup>hr, or greater than or equal to about 110 L/m<sup>2</sup>hr. In some instances, the permeate flux during the filtration step and/or at least a portion of the filtration step (e.g., concentration step(s) and/or diafiltration step, e.g., after 5 diafiltration volumes) at a transmembrane pressure 10 of between about 1 psi and about 20 psi (e.g., between about 10 psi and about 15 psi) may be less than or equal to about 120 L/m<sup>2</sup>hr, less than or equal to about 110 L/m<sup>2</sup>hr, less than or equal to about 100 L/m<sup>2</sup>hr, less than or equal to about 90 L/m<sup>2</sup>hr, less than or equal to about 80 L/m<sup>2</sup>hr, less than or equal to about 70 L/m<sup>2</sup>hr, less than or equal to about 60 L/m<sup>2</sup>hr, less than or equal to about 50 L/m<sup>2</sup>hr, less than or equal to about 40 15 L/m<sup>2</sup>hr, less than or equal to about 30 L/m<sup>2</sup>hr, or less than or equal to about 20 L/m<sup>2</sup>hr. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to about 10 L/m<sup>2</sup>hr and less than or equal to about 120 L/m<sup>2</sup>hr, greater than or equal to about 20 L/m<sup>2</sup>hr and less than or equal to about 110 L/m<sup>2</sup>hr).

In some embodiments, the particles comprise one or more of ionizable molecules, 20 polynucleotides, and optional components, such as sterols, neutral lipids, and a molecule capable of reducing particle aggregation (e.g., polyethylene glycol (PEG), polyethylene glycol-modified lipid).

In some embodiments, a particle described herein may include one or more ionizable molecules. The ionizable molecule may comprise a charged group and may 25 have a certain pKa. In certain embodiments, the pKa of the ionizable molecule may be greater than or equal to about 6, greater than or equal to about 6.2, greater than or equal to about 6.5, greater than or equal to about 6.8, greater than or equal to about 7, greater than or equal to about 7.2, greater than or equal to about 7.5, greater than or equal to about 7.8, greater than or equal to about 8. In some embodiments, the pKa of the 30 ionizable molecule may be less than or equal to about 10, less than or equal to about 9.8, less than or equal to about 9.5, less than or equal to about 9.2, less than or equal to about 9.0, less than or equal to about 8.8, or less than or equal to about 8.5. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 6 and less

than or equal to about 8.5). Other ranges are also possible. In embodiments in which more than one type of ionizable molecules are present in a particle, each type of ionizable molecule may independently have a pKa in one or more of the ranges described above.

5 In general, an ionizable molecule comprises one or more charged groups. In some embodiments, an ionizable molecule may be positively charged or negatively charged. For instance, an ionizable molecule may be positively charged. For example, an ionizable molecule may comprise an amine group. As used herein, the term “ionizable molecule” has its ordinary meaning in the art and may refer to a molecule or matrix  
10 comprising one or more charged moiety. As used herein, a “charged moiety” is a chemical moiety that carries a formal electronic charge, e.g., monovalent (+1, or -1), divalent (+2, or -2), trivalent (+3, or -3), etc. The charged moiety may be anionic (i.e., negatively charged) or cationic (i.e., positively charged). Examples of positively-charged moieties include amine groups (e.g., primary, secondary, and/or tertiary amines),  
15 ammonium groups, pyridinium group, guanidine groups, and imidazolium groups. In a particular embodiment, the charged moieties comprise amine groups. Examples of negatively- charged groups or precursors thereof, include carboxylate groups, sulfonate groups, sulfate groups, phosphonate groups, phosphate groups, hydroxyl groups, and the like. The charge of the charged moiety may vary, in some cases, with the environmental  
20 conditions, for example, changes in pH may alter the charge of the moiety, and/or cause the moiety to become charged or uncharged. In general, the charge density of the molecule and/or matrix may be selected as desired.

In some cases, an ionizable molecule may include one or more precursor moieties that can be converted to charged moieties. For instance, the ionizable molecule may  
25 include a neutral moiety that can be hydrolyzed to form a charged moiety, such as those described above. As a non-limiting specific example, the molecule or matrix may include an amide, which can be hydrolyzed to form an amine, respectively. Those of ordinary skill in the art will be able to determine whether a given chemical moiety carries a formal electronic charge (for example, by inspection, pH titration, ionic conductivity  
30 measurements, etc.), and/or whether a given chemical moiety can be reacted (e.g., hydrolyzed) to form a chemical moiety that carries a formal electronic charge.

It should be understood that the terms “charged” or “charged moiety” does not refer to a “partial negative charge” or “partial positive charge” on a molecule. The terms

“partial negative charge” and “partial positive charge” are given its ordinary meaning in the art. A “partial negative charge” may result when a functional group comprises a bond that becomes polarized such that electron density is pulled toward one atom of the bond, creating a partial negative charge on the atom. Those of ordinary skill in the art will, in general, recognize bonds that can become polarized in this way.

In some embodiments, an ionizable molecule is a lipid. For instance, the ionizable molecule may be a natural or synthetic lipid or lipid analog (i.e., lipophilic molecule). Non-limiting examples of natural or synthetic lipids or lipid analogs include fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids and polyketides (derived from condensation of ketoacyl subunits), and sterol lipids and prenol lipids (derived from condensation of isoprene subunits). Other ionizable molecules are also possible.

In some embodiments, the ionizable molecule is a charged lipid. For instance, in some embodiments, the ionizable molecule is a cationic lipid. In one embodiment, the cationic lipid may have a positively charged hydrophilic head and a hydrophobic tail that are connected via a linker structure. Non-limiting examples of cationic lipids include C12-200, DLin-DMA (1,2-dilinoleyloxy-3-dimethylaminopropane), DLin-K-DMA, DODMA (1,2-dioleyloxy-N,N-dimethylaminopropane), DLin-MC3-DMA, DLin-KC2-DMA, 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl]propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-[(9Z)-octadec-9-en-1-yloxy]methyl]propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl]propan-1-ol (Compound 4 in US20130150625), (20Z,23Z)-N,N-dimethylnonacos-20,23-dien-10-amine, (17Z,20Z)-N,N-dimethylhexacos-17,20-dien-9-amine, (1Z,19Z)-N,N-dimethylpentacos-1,19-dien-8-amine, (13Z,16Z)-N,N-dimethyldocos-13,16-dien-5-amine, (12Z,15Z)-N,N-dimethylhencosa-12,15-dien-4-amine, (14Z,17Z)-N,N-dimethyltricos-14,17-dien-6-amine, (15Z,18Z)-N,N-dimethyltetracos-15,18-dien-7-amine, (18Z,21Z)-N,N-dimethylheptacos-18,21-dien-10-amine, (15Z,18Z)-N,N-dimethyltetracos-15,18-dien-5-amine, (14Z,17Z)-N,N-dimethyltricos-14,17-dien-4-amine, (19Z,22Z)-N,N-dimeihyoctacos-19,22-dien-9-amine, (18Z,21 Z)-N,N-dimethylheptacos- 18 ,21 -dien-

8-amine, (17Z,20Z)-N,N-dimethylhexacos-17,20-dien-7-amine, (16Z,19Z)-N,N-dimethylpentacos-16,19-dien-6-amine, (22Z,25Z)-N,N-dimethylhentriaconta-22,25-dien-10-amine, (21Z,24Z)-N,N-dimethyltriaconta-21,24-dien-9-amine, (18Z)-N,N-dimethylheptacos-18-en-10-amine, (17Z)-N,N-dimethylhexacos-17-en-9-amine,  
5 (19Z,22Z)-N,N-dimethyloctacos-19,22-dien-7-amine, N,N-dimethylheptacosan-10-amine, (20Z,23Z)-N-ethyl-N-methylnonacos-20,23-dien-10-amine, 1-[(11Z,14Z)-1-nonylicos-11,14-dien-1-yl]pyrrolidine, (20Z)-N,N-dimethylheptacos-20-en-10-amine, (15Z)-N,N-dimethylheptacos-15-en-10-amine, (14Z)-N,N-dimethylnonacos-14-en-10-amine, (17Z)-N,N-dimethylnonacos-17-en-10-amine, (24Z)-N,N-dimethyltritiacont-24-  
10 en-10-amine, (20Z)-N,N-dimethylnonacos-20-en-10-amine, (22Z)-N,N-dimethylhentriacont-22-en-10-amine, (16Z)-N,N-dimethylpentacos-16-en-8-amine, (12Z,15Z)-N,N-dimethyl-2-nonylhenicos-12,15-dien-1-amine, (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]eptadecan-8-amine, 1-[(1S,2R)-2-hexylcyclopropyl]-N,N-  
15 dimethylnonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine, N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine, N,N-dimethyl-1-[(1S,2S)-2-[(1R,2R)-2-pentylcyclopropyl]methyl]cyclopropyl]nonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N-dimethyl-[(1R,2S)-2-undecylcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7-  
20 [(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine, 1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine, R,N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, S,N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-  
25 2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine, (2S)-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidine, (2S)-1-(hexyloxy)-N,N-dimethyl-3-  
[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine; (2S)-N,N-dimethyl-1-  
[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine, (2S)-1-

[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine,  
 (2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-  
 amine, 1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-  
 amine, 1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-  
 5 amine, (2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-  
 dimethylpropan-2-amine, (2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-  
 dimethylpropan-2-amine, 1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-  
 (octyloxy)propan-2-amine, 1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-  
 (octyloxy)propan-2-amine, (2R)-N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-  
 10 octadeca-9,12-dien-1-yloxy]propan-2-amine, (2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-  
 dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-  
 (octyloxy)-3-({8-[(1S,2S)-2-[(1R,2R)-2-  
 pentylcyclopropyl]methyl}cyclopropyl)octyl}oxy)propan-2-amine, N,N-dimethyl-1-{{8-  
 (2-oc1ylcyclopropyl)octyl}oxy}-3-(octyloxy)propan-2-amine and (11E,20Z,23Z)-N,N-  
 15 dimethylnonacos-11,20,2-trien-10-amine, and pharmaceutically acceptable salts or  
 stereoisomers thereof. In embodiments in which more than one type of ionizable  
 molecules are present in a particle, each type of ionizable molecule may independently  
 be chosen from the ionizable molecules described herein.

In some embodiments, an ionizable cationic lipid is selected from the group  
 20 consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),  
 dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-  
 yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and pharmaceutically  
 acceptable salts or stereoisomers thereof.

In some embodiments, the ionizable molecule comprises a nitrogen atom. In  
 25 some such embodiments, a molar ratio of nitrogen atoms in the ionizable molecules to  
 the phosphates in the polynucleotides (N:P ratio) may be greater than or equal to about  
 1:1, greater than or equal to about 2:1, greater than or equal to about 3:1, greater than or  
 equal to about 5:1, greater than or equal to about 8:1, greater than or equal to about 10:1,  
 greater than or equal to about 12:1, greater than or equal to about 15:1, or greater than or  
 30 equal to about 20:1. In some embodiments, the N:P ratio may be less than or equal to  
 about 20:1, less than or equal to about 18:1, less than or equal to about 15:1, less than or  
 equal to about 12:1, less than or equal to about 10:1, less than or equal to about 8:1, or  
 less than or equal to about 5:1. Combinations of the above referenced ranges are also

possible (e.g., greater than or equal to 1:1 and less than or equal to about 20:1). Other ranges are also possible. In embodiments in which more than one type of ionizable molecules are present in a particle, each type of ionizable molecule may independently have a N:P ratio in one or more of the ranges described above.

5           In some embodiments, the ionizable molecule may be a lipid bound to a polycation. Non-limiting examples of polycations may include natural polycations (e.g., chitosan), synthetic polycations (e.g., polyamines, such as polyethylene imine) a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine.

10           The ionizable molecule may have any suitable molecular weight. In certain embodiments, the molecular weight of an ionizable molecule is less than or equal to about 2,500 g/mol, less than or equal to about 2,000 g/mol, less than or equal to about 1,500 g/mol, less than or equal to about 1,250 g/mol, less than or equal to about 1,000 g/mol, less than or equal to about 900 g/mol, less than or equal to about 800 g/mol, less  
15           than or equal to about 700 g/mol, less than or equal to about 600 g/mol, less than or equal to about 500 g/mol, less than or equal to about 400 g/mol, less than or equal to about 300 g/mol, less than or equal to about 200 g/mol, or less than or equal to about 100 g/mol. In some instances, the molecular weight of an ionizable molecule is greater than  
20           or equal to about 100 g/mol, greater than or equal to about 200 g/mol, greater than or equal to about 300 g/mol, greater than or equal to about 400 g/mol, greater than or equal to about 500 g/mol, greater than or equal to about 600 g/mol, greater than or equal to about 700 g/mol, greater than or equal to about 1000 g/mol, greater than or equal to about 1,250 g/mol, greater than or equal to about 1,500 g/mol, greater than or equal to about 1,750 g/mol, greater than or equal to about 2,000 g/mol, or greater than or equal to  
25           about 2,250 g/mol. Combinations of the above ranges (e.g., at least about 200 g/mol and less than or equal to about 2,500 g/mol) are also possible. In embodiments in which more than one type of ionizable molecules are present in a particle, each type of ionizable molecule may independently have a molecular weight in one or more of the ranges described above.

30           In some embodiments, the percentage (e.g., by weight, or by mole) of a single type of ionizable molecule and/or of all the ionizable molecules within a particle may be greater than or equal to about 30%, greater than or equal to about 35%, greater than or equal to about 40%, greater than or equal to about 42%, greater than or equal to about



45%, greater than or equal to about 48%, greater than or equal to about 50%, greater than or equal to about 52%, greater than or equal to about 55%, greater than or equal to about 58%, greater than or equal to about 60%, greater than or equal to about 62%, greater than or equal to about 65%, or greater than or equal to about 68%. In some instances, the percentage (e.g., by weight, or by mole) may be less than or equal to about 70%, less than or equal to about 68%, less than or equal to about 65%, less than or equal to about 62%, less than or equal to about 60%, less than or equal to about 58%, less than or equal to about 55%, less than or equal to about 52%, less than or equal to about 50%, or less than or equal to about 48%. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 30% and less than or equal to about 70%, greater than or equal to 40% and less than or equal to about 65%). In embodiments in which more than one type of ionizable molecules are present in a particle, each type of ionizable molecule may independently have a percentage (e.g., by weight, or by mole) in one or more of the ranges described above. The percentage (e.g., by weight, or by mole) may be determined by extracting the ionizable molecule(s) from the dried particles using, e.g., organic solvents, and measuring the quantity of the agent using high pressure liquid chromatography (i.e., HPLC), liquid chromatography-mass spectrometry, nuclear magnetic resonance, or mass spectrometry. Those of ordinary skill in the art would be knowledgeable of techniques to determine the quantity of a component using the above-referenced techniques. For example, HPLC may be used to quantify the amount of a component, by, e.g., comparing the area under the curve of a HPLC chromatogram to a standard curve.

As described herein, a particle may include a polynucleotide, i.e., a polymer of nucleotides. In some embodiments, a particle includes more than one (e.g., at least 2, 3, 4, 5, 6, etc. types of polynucleotides). Typically, a polynucleotide comprises at least three nucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5 bromouridine, C5 fluorouridine, C5 iodouridine, C5 methylcytidine, 7 dezaadenosine, 7 dezaguanosine, 8 oxoadenosine, 8 oxoguanosine, O(6) methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methylated bases), intercalated bases, modified sugars (e.g., 2'-

fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose), or modified phosphate groups (e.g., phosphorothioates and 5' N phosphoramidite linkages). In some embodiments, the polynucleotide is mRNA, or alternative or modified mRNA. In some embodiments, the polynucleotide comprises at least about 50 nucleotides, at least about 100 nucleotides, at least about 250 nucleotides, at least about 500 nucleotides, at least about 750 nucleotides, at least about 1,000 nucleotides, at least about 1,500 nucleotides, at least about 2,000 nucleotides, at least about 2,500 nucleotides, at least about 3,000 nucleotides, at least about 3,500 nucleotides or at least about 4,000 nucleotides and less than about 10,000 nucleotides (e.g., between about 100 and about 5,000 nucleotides).

10 In some embodiments, the particle comprises one or more sterols (e.g., cholesterol). A non-limiting example of a sterol include cholesterol.

The sterol molecules may have any suitable molecular weight. In certain embodiments, the molecular weight of a sterol molecule may be less than or equal to about 2,500 g/mol, less than or equal to about 2,000 g/mol, less than or equal to about 1,500 g/mol, less than or equal to about 1,250 g/mol, less than or equal to about 1,000 g/mol, less than or equal to about 900 g/mol, less than or equal to about 800 g/mol, less than or equal to about 700 g/mol, less than or equal to about 600 g/mol, less than or equal to about 500 g/mol, less than or equal to about 400 g/mol, less than or equal to about 300 g/mol, less than or equal to about 200 g/mol, or less than or equal to about 100 g/mol. In some instances, the molecular weight of a sterol molecule may be greater than or equal to about 100 g/mol, greater than or equal to about 200 g/mol, greater than or equal to about 300 g/mol, greater than or equal to about 400 g/mol, greater than or equal to about 500 g/mol, greater than or equal to about 600 g/mol, greater than or equal to about 700 g/mol, greater than or equal to about 1000 g/mol, greater than or equal to about 1,250 g/mol, greater than or equal to about 1,500 g/mol, greater than or equal to about 1,750 g/mol, greater than or equal to about 2,000 g/mol, or greater than or equal to about 2,250 g/mol. Combinations of the above ranges (e.g., at least about 200 g/mol and less than or equal to about 2,500 g/mol) are also possible. In embodiments in which more than one type of sterol are present in a particle, each type of sterol may independently have a molecular weight in one or more of the ranges described above.

30 In some embodiments, the percentage (e.g., by weight, or by mole) of a single type of sterol (e.g., cholesterol) and/or of all the sterols in a particle may be greater than or equal to about 0.5%, greater than or equal to about 1%, greater than or equal to about

2%, greater than or equal to about 4%, greater than or equal to about 6%, greater than or equal to about 8%, greater than or equal to about 10%, greater than or equal to about 15%, greater than or equal to about 20%, greater than or equal to about 25%, greater than or equal to about 30%, greater than or equal to about 35%, greater than or equal to about 40%, greater than or equal to about 45%, or greater than or equal to about 50%. In some instances, the percentage (e.g., by weight, or by mole) may be less than or equal to about 60%, less than or equal to about 55%, less than or equal to about 50%, less than or equal to about 45%, less than or equal to about 40%, less than or equal to about 35%, less than or equal to about 30%, less than or equal to about 25%, less than or equal to about 20%, or less than or equal to about 15%. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 30% and less than or equal to about 60%). In embodiments in which more than one type of sterol are present in a particle, each type of sterol may independently have a percentage (e.g., by weight, or by mole) with respect to the particle in one or more of the ranges described above. The percentage (e.g., by weight, or by mole) may be determined as described above with respect to ionizable molecules.

In some embodiments, the particle comprises one or more neutral lipids (i.e., neutrally-charged lipids). Non-limiting examples of neutral lipids include DSPC, DPPC, POPC, DOPE and SM.

In some embodiments, a lipid described herein may be a cleavable lipid. Non-limiting examples of cleavable lipids include HGT4001, HGT4002, HGT4003, HGT4004 and/or HGT4005.

The neutral lipids may have any suitable molecular weight. In certain embodiments, the molecular weight of a neutral lipid may be less than or equal to about 2,500 g/mol, less than or equal to about 2,000 g/mol, less than or equal to about 1,500 g/mol, less than or equal to about 1,250 g/mol, less than or equal to about 1,000 g/mol, less than or equal to about 900 g/mol, less than or equal to about 800 g/mol, less than or equal to about 700 g/mol, less than or equal to about 600 g/mol, less than or equal to about 500 g/mol, less than or equal to about 400 g/mol, less than or equal to about 300 g/mol, less than or equal to about 200 g/mol, or less than or equal to about 100 g/mol. In some instances, the molecular weight of a neutral lipid may be greater than or equal to about 100 g/mol, greater than or equal to about 200 g/mol, greater than or equal to about 300 g/mol, greater than or equal to about 400 g/mol, greater than or equal to about 500

g/mol, greater than or equal to about 600 g/mol, greater than or equal to about 700 g/mol, greater than or equal to about 1000 g/mol, greater than or equal to about 1,250 g/mol, greater than or equal to about 1,500 g/mol, greater than or equal to about 1,750 g/mol, greater than or equal to about 2,000 g/mol, or greater than or equal to about 2,250 g/mol.

5 Combinations of the above ranges (e.g., at least about 200 g/mol and less than or equal to about 2,500 g/mol) are also possible. In embodiments in which more than one type of neutral lipid are present in a particle, each type of neutral lipid may independently have a molecular weight in one or more of the ranges described above.

In some embodiments, the percentage (e.g., by weight, or by mole) of a single  
10 type of neutral lipid and/or of all the neutral lipids in a particle may be greater than or equal to about 0.5%, greater than or equal to about 1%, greater than or equal to about 2%, greater than or equal to about 4%, greater than or equal to about 6%, greater than or equal to about 8%, greater than or equal to about 10%, greater than or equal to about 15%, or greater than or equal to about 20%. In some instances, the percentage (e.g., by  
15 weight, or by mole) may be less than or equal to about 20%, less than or equal to about 18%, less than or equal to about 15%, less than or equal to about 12%, less than or equal to about 10%, less than or equal to about 8%, less than or equal to about 6%, less than or equal to about 5%, less than or equal to about 4%, or less than or equal to about 3%. Combinations of the above referenced ranges are also possible (e.g., greater than or  
20 equal to 0.5% and less than or equal to about 20%). The percentage (e.g., by weight, or by mole) may be determined as described above with respect to ionizable molecules. In embodiments in which more than one type of neutral lipid are present in a particle, each type of neutral lipid may independently have a percentage (e.g., by weight, or by mole) with respect to the particle in one or more of the ranges described above.

25 In some embodiments, the particle comprises one or more molecules capable of reducing particle aggregation. Non-limiting examples of molecules capable of reducing particle aggregation include PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol), and PEG-DPG  
30 (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). Other molecules are also possible.

The molecule capable of reducing particle aggregation may have any suitable molecular weight. In certain embodiments, the molecular weight of a molecule capable

of reducing particle aggregation may be less than or equal to about 2,500 g/mol, less than or equal to about 2,000 g/mol, less than or equal to about 1,500 g/mol, less than or equal to about 1,250 g/mol, less than or equal to about 1,000 g/mol, less than or equal to about 900 g/mol, less than or equal to about 800 g/mol, less than or equal to about 700 g/mol, less than or equal to about 600 g/mol, less than or equal to about 500 g/mol, less than or equal to about 400 g/mol, less than or equal to about 300 g/mol, less than or equal to about 200 g/mol, or less than or equal to about 100 g/mol. In some instances, the molecular weight of a molecule capable of reducing particle aggregation may be greater than or equal to about 100 g/mol, greater than or equal to about 200 g/mol, greater than or equal to about 300 g/mol, greater than or equal to about 400 g/mol, greater than or equal to about 500 g/mol, greater than or equal to about 600 g/mol, greater than or equal to about 700 g/mol, greater than or equal to about 1000 g/mol, greater than or equal to about 1,250 g/mol, greater than or equal to about 1,500 g/mol, greater than or equal to about 1,750 g/mol, greater than or equal to about 2,000 g/mol, or greater than or equal to about 2,250 g/mol. Combinations of the above ranges (e.g., at least about 200 g/mol and less than or equal to about 2,500 g/mol) are also possible. In embodiments in which more than one type of molecule capable of reducing particle aggregation are present in a particle, each type of molecule may independently have a molecular weight in one or more of the ranges described above.

In some embodiments, the percentage (e.g., by weight, or by mole) of a single type of molecule capable of reducing particle aggregation and/or of all the molecules capable of reducing particle aggregation in a particle may be greater than or equal to about 0.5%, greater than or equal to about 1%, greater than or equal to about 2%, greater than or equal to about 4%, greater than or equal to about 6%, greater than or equal to about 8%, greater than or equal to about 10%, greater than or equal to about 12%, greater than or equal to about 15%, or greater than or equal to about 18%. In some instances, the percentage (e.g., by weight, or by mole) may be less than or equal to about 20%, less than or equal to about 18%, less than or equal to about 15%, less than or equal to about 12%, less than or equal to about 10%, less than or equal to about 8%, less than or equal to about 7%, less than or equal to about 6%, less than or equal to about 5%, or less than or equal to about 4%. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 0.5% and less than or equal to about 7%, greater than or equal to 2% and less than or equal to about 20%). In embodiments in which more than

one type of molecule capable of reducing particle aggregation are present in a particle, each type of molecule may independently have a percentage (e.g., by weight, or by mole) with respect to the particle in one or more of the ranges described above. The percentage (e.g., by weight, or by mole) may be determined as described above with respect to  
5 ionizable molecules.

In some embodiments, the particles may comprise a reactive component attached to dienophile as a chemically cleavable group which may provoking the release in vitro of the formulation and/or the polynucleotide.

In some embodiments, the particles may comprise a polymer, such as  
10 polyethylenimine (PEI), dithiobis(succinimidylpropionate) (DSP), Dimethyl-3,3'-dithiobispropionimidate (DTBP), poly(ethylene imine) biscarbamate (PEIC), poly(L-lysine) (PLL), histidine modified PLL, poly(N-vinylpyrrolidone) (PVP), poly(propylenimine (PPI), poly(amidoamine) (PAMAM), poly(amido ethylenimine) (SS-PAEI), triethylenetetramine (TETA), poly( $\beta$ -aminoester), poly(4-hydroxy-L-proline ester) (PHP), poly(allylamine), poly( $\alpha$ -[4-aminobutyl]-L-glycolic acid (PAGA),  
15 Poly(D,L-lactic-co-glycolid acid (PLGA), Poly(N-ethyl-4-vinylpyridinium bromide), poly(phosphazene)s (PPZ), poly(phosphoester)s (PPE), poly(phosphoramidate)s (PPA), poly(N-2-hydroxypropylmethacrylamide) (pHPMA), poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA), poly(2-aminoethyl propylene phosphate) PPE\_EA,  
20 chitsoan, galactosylated chitosan, N-dodecylated chitosan, histone, collagen or dextran-spermine, and combinations thereof. In one embodiment, the polymer may be an inert polymer such as, but not limited to, PEG. In one embodiment, the polymer may be a cationic polymer such as, but not limited to, PEI, PLL, TETA, poly(allylamine), Poly(N-ethyl-4-vinylpyridinium bromide), pHPMA and pDMAEMA. In one embodiment, the  
25 polymer may be a biodegradable PEI such as, but not limited to, DSP, DTBP and PEIC. In one embodiment, the polymer may be biodegradable such as, but not limited to, histine modified PLL, SS-PAEI, poly( $\beta$ -aminoester), PHP, PAGA, PLGA, PPZ, PPE, PPA and PPE-EA.

In some embodiments, the particles described herein may be liposomes including  
30 one or more polynucleotides. In some cases, liposomes may encapsulate (e.g., partially, completely) the one or more polynucleotides.

In certain embodiments, a particle, formulation, or composition described herein has components and/or a configuration as described in International Pub. No.

WO2013/090648, entitled “Modified nucleoside, nucleotide, and nucleic acid compositions”, filed Dec. 14, 2012, and/or U.S. Pub. No. US2012/0295832, entitled “Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds”, filed May 8, 2012, each of which is incorporated herein by reference in its entirety for all purposes.

In some embodiments, the ratio of one or more components (e.g., lipids, all other components) to polynucleotides (e.g., mRNA or alternative or modified mRNA alternative or modified mRNA) in the particles may be greater than or equal to about 5:1, greater than or equal to about 10:1, greater than or equal to about 15:1, greater than or equal to about 20:1, greater than or equal to about 25:1, greater than or equal to about 30:1, greater than or equal to about 35:1, greater than or equal to about 40:1, greater than or equal to about 45:1, greater than or equal to about 50:1, greater than or equal to about 55:1, or greater than or equal to about 60:1. In some embodiments, the ratio of one or more components to polynucleotides may be less than or equal to about 70:1, less than or equal to about 65:1, less than or equal to about 60:1, less than or equal to about 55:1, less than or equal to about 50:1, less than or equal to about 45:1, less than or equal to about 40:1, less than or equal to about 35:1, less than or equal to about 30:1, less than or equal to about 25:1, less than or equal to about 20:1, less than or equal to about 15:1, or less than or equal to about 10:1. Combinations of the above referenced ranges are also possible (e.g., greater than or equal to 1:1 and less than or equal to about 20:1). Other ranges are also possible.

In some embodiments, the particles comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.

In one set of embodiments, a particle formulation (e.g., lipid nanoparticle formulation) consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and

(iv) a PEG-lipid, *e.g.*, PEG-DMG or PEG-cDMA, in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% PEG-lipid.

In one set of embodiments, a formulation includes from about 25% to about 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), *e.g.*, from about 35 to about 65%, from about 45 to about 65%, about 60%, about 57.5%, about 50% or about 40% on a molar basis.

In one set of embodiments, a formulation includes from about 0.5% to about 15% on a molar basis of a neutral lipid *e.g.*, from about 3 to about 12%, from about 5 to about 10% or about 15%, about 10%, or about 7.5% on a molar basis. Exemplary neutral lipids include, but are not limited to, DSPC, POPC, DPPC, DOPE and SM. In one set of embodiments, the formulation includes from about 5% to about 50% on a molar basis of a sterol (*e.g.*, about 15 to about 45%, about 20 to about 40%, about 40%, about 38.5%, about 35%, or about 31% on a molar basis. An exemplary sterol is cholesterol. In one set of embodiments, the formulation includes from about 0.5% to about 20% on a molar basis of the PEG or PEG-modified lipid (*e.g.*, about 0.5 to about 10%, about 0.5 to about 5%, about 1.5%, about 0.5%, about 1.5%, about 3.5%, or about 5% on a molar basis. In one set of embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In other embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Exemplary PEG-modified lipids include, but are not limited to, PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA (further discussed in Reyes et al. *J. Controlled Release*, 107, 276-287 (2005).)

In one set of embodiments, a formulations includes 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of a neutral lipid, 5-50% of a sterol, and 0.5-20% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation includes 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),



dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of a neutral lipid, 15-45% of a sterol, and 0.5-10% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation includes 45-65% of a cationic lipid  
5 selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),  
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of a neutral lipid, 25-40% of a sterol, and 0.5-10% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation includes about 60% of a cationic lipid  
10 selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),  
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.5% of a neutral lipid, about 31 % of a sterol, and about 1.5% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation includes about 50% of a cationic lipid  
15 selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),  
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of a neutral lipid, about 38.5 % of a sterol, and about 1.5% of a PEG or PEG-modified lipid  
20 on a molar basis.

In one set of embodiments, a formulation includes about 50% of a cationic lipid  
selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),  
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of a  
25 neutral lipid, about 35 % of a sterol, about 4.5% or about 5% of a PEG or PEG-modified  
lipid, and about 0.5% of a targeting lipid on a molar basis. Non-limiting examples of a  
targeting lipid include lipids that are conjugated to a peptide, a small molecule, an  
antibody, an aptamer, and/or or fragment protein.

In one set of embodiments, a formulations includes about 40% of a cationic lipid  
30 selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),  
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 15% of a

neutral lipid, about 40% of a sterol, and about 5% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation includes about 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.1% of a neutral lipid, about 34.3% of a sterol, and about 1.4% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation includes about 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (1. *Controlled Release*, 107, 276-287 (2005)), about 7.5% of a neutral lipid, about 31.5 % of a sterol, and about 3.5% of a PEG or PEG-modified lipid on a molar basis.

In one set of embodiments, a formulation consists essentially of a lipid mixture in molar ratios of about 20-70% cationic lipid: 5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid. For instance, the formulation may have in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid. In some such cases, the formulation includes (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), DSPC, cholesterol, and PEG2000-DMG.

In particular embodiments, the molar lipid ratio is approximately 50/10/38.5/1.5 (mol% cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol% cationic lipid/ neutral lipid, e.g., DPPC/Chol/ PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol% cationic lipid/ neutral lipid, e.g., DSPC/Chol/ PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol% cationic lipid/ neutral lipid, e.g., DSPC/Chol/ PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/ neutral lipid, e.g., DSPC/Chol/ PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol% cationic lipid/ neutral lipid, e.g., DSPC/Chol/ PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol% cationic lipid/ neutral lipid, e.g., DSPC/Chol/ PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol% cationic lipid/ neutral lipid, e.g., DSPC/Chol/ PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

Exemplary formulations (e.g., lipid nanoparticle compositions) and methods of making the same are described, for example, in Semple et al. (2010) *Nat. Biotechnol.*

28:172-176; Jayarama et al. (2012), *Angew. Chem. Int. Ed.*, 51: 8529–8533; and Maier et al. (2013) *Molecular Therapy* **21**, 1570-1578 (each of which is incorporated herein by reference).

In some cases, the particles in the filtered suspension and/or the particles of a composition/formulation described herein may have a relatively narrow distribution in a cross-sectional dimension. For instance, in certain embodiments, the coefficient of variation of a cross-sectional dimension (e.g., diameter) of the particles in a suspension and/or composition/formulation may be less than or equal to about 30%, less than or equal to about 25%, less than or equal to about 20%, less than or equal to about 15%, less than or equal to about 10%, or less than or equal to about 5%. In certain embodiments, the coefficient of variation of a cross-sectional dimension (e.g., diameter) of the particles in a suspension and/or composition/formulation may be greater than or equal to about 1%, greater than or equal to about 3%, greater than or equal to about 5%, greater than or equal to about 7%, or greater than or equal to about 10%. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to about 1% and less than or equal to about 20%, greater than or equal to about 5% and less than or equal to about 20%).

In some embodiments, the particles in the filtered suspension and/or the particles of a composition/formulation described herein may have a relatively small average cross-sectional dimension (e.g., diameter). For instance, in some embodiments, the average cross-sectional dimension (e.g., average diameter) of the particles in a filtered suspension or composition/formulation may be less than or equal to about 1,000 nm, less than or equal to about 800 nm, less than or equal to about 600 nm, less than or equal to about 500 nm, less than or equal to about 400 nm, less than or equal to about 300 nm, less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 120 nm, less than or equal to about 100 nm, or less than or equal to about 50 nm. In some embodiments, the average cross-sectional dimension (e.g., average diameter) of the particles in a filtered suspension or composition/formulation may be greater than or equal to about 10 nm, greater than or equal to about 50 nm, greater than or equal to about 70 nm, greater than or equal to about 100 nm, greater than or equal to about 200 nm, greater than or equal to about 300 nm, greater than or equal to about 400 nm, greater than or equal to about 500 nm, greater than or equal to about 600 nm, greater than or equal to about 700 nm, greater than or equal to about 800 nm, or greater than or equal to about

900 nm. combinations of the above-referenced ranges are also possible (e.g., greater than or equal to about 50 nm and less than or equal to about 200 nm, greater than or equal to about 70 nm and less than or equal to about 120 nm).

As used herein, the diameter of a particle for a non-spherical particle is the diameter of a perfect mathematical sphere having the same volume as the non-spherical particle. In general, the particles described herein are approximately spherical; however the particles are not necessarily spherical but may assume other shapes (e.g., discs, rods) as well.

In some embodiments, the particles are microparticles. In certain embodiments, the particles may have an average cross-sectional dimension of less than 1 mm. For instance, in some embodiments, the average cross-sectional dimension of the particles may be less than or equal to about 1,000 microns, less than or equal to about 500 microns, less than or equal to about 100 microns, less than or equal to about 50 microns, less than or equal to about 10 microns, or less than or equal to about 5 microns. In some embodiments, the average cross-sectional dimension of the particles may be greater than or equal to about 1 micron. Combinations of the above-referenced ranges are also possible.

In some embodiments, the particles are biocompatible. As used herein, the term “biocompatible” is intended to describe a material (e.g., particles, excipients) that is not toxic to cells. Particles are “biocompatible” if their addition to cells in vitro results in less than about 20% (e.g., less than about 15%, less than about 10%, less than about 5%, less than about 3%, less than about 2%, less than about 1%) cell death, and their administration in vivo does not substantially induce inflammation or other such adverse effects.

In some embodiments, the particles are biodegradable. As used herein, “biodegradable” compounds are those that, when introduced into cells, are broken down by the cellular machinery or by hydrolysis into components that the cells can either reuse or dispose of without significant toxic effects on the cells (i.e., less than about 20% (e.g., less than about 15%, less than about 10%, less than about 5%, less than about 3%, less than about 2%, less than about 1%) of the cells are killed when the components are added to cells in vitro). The components preferably do not induce inflammation or other adverse effects in vivo. In certain embodiments, the chemical reactions relied upon to break down the biodegradable compounds are uncatalyzed. For example, the inventive

materials may be broken down in part by the hydrolysis of the polymeric material of the inventive coated particles.

In some embodiments, a method described herein may comprise adding an additional component to the particle. For instance, in some embodiments, a method may  
5 comprise attaching a surface modifying agent to the surface of the particle. In general, any suitable chemical compound can be attached to particle. Non-limiting examples of chemical compounds include small molecules, polynucleotides, proteins, peptides, metals, polymers, oligomers, organometallic complexes, lipids, carbohydrates, etc. The chemical compound may modify any property of particle including surface charge,  
10 hydrophilicity, hydrophobicity, zeta potential, size, etc. In certain embodiments, the chemical compound is a polymer such as polyethylene glycol (PEG). In certain embodiments, the chemical compound is a targeting moiety used to direct the particles to a particular cell, collection of cells, tissue, or organ system and/or to promote endocytosis or phagocytosis of the particle. Any targeting moiety known in the art of  
15 drug delivery may be used.

In some embodiments, the particles described herein may be made in a sterile environment.

In some embodiments, the particles may be created using microfluidic technology (see, e.g., Whitesides, George M., "The Origins and the Future of Microfluidics". *Nature*,  
20 2006 442: 368-373; Stroock et al., "Chaotic Mixer for Microchannels". *Science*, 2002 295: 647-651; and Valencia et al., "Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy". *ACS Nano* 2013 (DOI/10.1021/nn403370e). As a non-limiting example, controlled microfluidic formulation includes a passive method for mixing streams of steady pressure-driven  
25 flows in micro channels at a low Reynolds number as described, e.g., in Stroock et al., "Chaotic Mixer for Microchannels". *Science*, 2002 295: 647-651).

In one embodiment, the particles may be created using a micromixer chip such as, but not limited to, those from Harvard Apparatus (Holliston, MA) or Dolomite Microfluidics (Royston, UK). A micromixer chip can be used for rapid mixing of two or  
30 more fluid streams with a split and recombine mechanism.

In one embodiment, the particles may be created using NanoAssembler Y-mixer chip technology.

Particles formed via the methods described herein may be particularly useful for administering an agent to a subject in need thereof. In some embodiments, the particles are used to deliver a pharmaceutically active agent. In some instances, the particles are used to deliver a prophylactic agent. The particles may be administered in any way  
5 known in the art of drug delivery, for example, orally, parenterally, intravenously, intramuscularly, subcutaneously, intradermally, transdermally, intrathecally, submucosally, sublingually, rectally, vaginally, etc.

Once the particles have been prepared, they may be combined with pharmaceutically acceptable excipients to form a pharmaceutical composition. As would  
10 be appreciated by one of skill in this art, the excipients may be chosen based on the route of administration as described below, the agent being delivered, and the time course of delivery of the agent.

Pharmaceutical compositions described herein and for use in accordance with the embodiments described herein may include a pharmaceutically acceptable excipient. As  
15 used herein, the term “pharmaceutically acceptable excipient” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable excipients are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl  
20 cellulose, methylcellulose, hydroxypropylmethylcellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as  
25 magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen free water; isotonic saline; citric acid, acetate salts, Ringer’s solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can  
30 also be present in the composition, according to the judgment of the formulator. The pharmaceutical compositions of this invention can be administered to humans and/or to animals, orally, rectally, parenterally, intracisternally, intravaginally, intranasally,

intraperitoneally, topically (as by powders, creams, ointments, or drops), buccally, or as an oral or nasal spray.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredients (i.e., the particles), the liquid dosage forms may contain inert diluents  
5 commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor,  
10 and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable preparations, for example, sterile injectable aqueous or oleaginous  
15 suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, ethanol, U.S.P.,  
20 and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, by filtration through a  
25 bacteria retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

Compositions for rectal or vaginal administration may be suppositories which can be prepared by mixing the particles with suitable non irritating excipients or carriers such  
30 as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the particles are mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a pharmaceutical composition include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The particles are admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also possible.

The ointments, pastes, creams, and gels may contain, in addition to the particles of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.



Powders and sprays can contain, in addition to the particles of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

5 Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the particles in a proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the particles in a polymer matrix or gel.

10 Kits for use in preparing or administering the particles are also provided. A kit for forming particles may include any solvents, solutions, buffer agents, acids, bases, salts, targeting agent, etc. needed in the particle formation process. Different kits may be available for different targeting agents. In certain embodiments, the kit includes materials or reagents for purifying, sizing, and/or characterizing the resulting particles.  
15 The kit may also include instructions on how to use the materials in the kit. The one or more agents (e.g., pharmaceutically active agent) to be encapsulated in the particle are typically provided by the user of the kit.

Kits are also provided for using or administering the particles or pharmaceutical compositions thereof. The particles may be provided in convenient dosage units for  
20 administration to a subject. The kit may include multiple dosage units. For example, the kit may include 1-100 dosage units. In certain embodiments, the kit includes a week supply of dosage units, or a month supply of dosage units. In certain embodiments, the kit includes an even longer supply of dosage units. The kits may also include devices for administering the particles or a pharmaceutical composition thereof. Exemplary devices  
25 include syringes, spoons, measuring devices, etc. The kit may optionally include instructions for administering the particles (e.g., prescribing information).

“Composition”: The terms “composition” and “formulation” are used interchangeably.

30 “Condition”: As used herein, the terms “condition,” “disease,” and “disorder” are used interchangeably.

The following examples are intended to illustrate certain embodiments of the present invention, but do not exemplify the full scope of the invention.

## EXAMPLES

## EXAMPLE 1

This example describes the effect of incubation time and pH on encapsulation efficiency of nanoparticles containing mRNA and an ionizable molecule (i.e., MC3 lipid). The particles also contained other lipids and a sterol and are referred to in the examples as lipid nanoparticles. Encapsulation percentages of greater than 90% were obtained under acidic conditions when incubations times were at least 300 seconds under acidic conditions.

Lipid nanoparticles were prepared using a micromixer channel in a T-configuration at sufficient flow rates to facilitate rapid mixing of an aqueous solution containing mRNA and an ethanol solution containing lipids. The mixing led to nanoprecipitation and ultimately particle formation. The lipids used in this experiment were PEG-DMG (a diffusible PEG lipid which may impart physical stability to the lipid nanoparticle), cholesterol (e.g., which may provide structural support to the lipid nanoparticle), DSPC (a phospholipid known to be involved in lipid fusogenicity with the endosome compartment of a cell), and MC3 (an ionizable cationic lipid that becomes protonated in a low pH endosomal environment, which may lead to escape of the endosome compartment to the cytosol).

The ethanol solution was prepared by dissolving MC3, DSPC, cholesterol, and PEG-DMG at a mol% ratio of 50:10:38.5:1.5 in 200 proof ethanol to obtain a final lipid concentration of 12.5 mM. The stock ethanol solution was then filtered through a 0.8/0.2 micron filter. The ethanol solution was then stored at room temperature until use.

The aqueous solution contained about 0.2 mg/mL of mRNA in 20 mM sodium citrate pH 4.0. A tonicity modifier, sucrose, was added to adjust the total osmolarity of the solution. Once prepared, the aqueous solution was filtered through a 0.8/0.2 micron filter. The aqueous solution was then stored at room temperature until use.

Lipid nanoparticles were assembled by mixing the aqueous mRNA and lipid solutions using an impinging jet mixer in a Tee configuration. The flow ratios were offset between lipid and aqueous solutions, resulting in a total ethanol content at the site of mixing of 33%. The total cumulative flow rate of the aqueous and lipid solutions was 125 mL/min. The lipid nanoparticles produced were then diluted in-line at a 1:1 ratio with 20 mM sodium citrate pH 6.0 which was then followed by a second in-line dilution

at 2:1 ratio with 1x citrate buffered saline (CBS). In this example, the first dilution was set at a cumulative flow rate of 125 mL/min followed by a second dilution at a cumulative flow rate of 250 mL/min. The particles were allowed to form for different incubation times. The incubation time was measured at the point at which the all of the components in the lipid and aqueous solutions were combined and ended with removal of the particles in this example.

To investigate incubation times and the influence on percent encapsulation, the pH of the dilution buffers were adjusted to increase solution pH from less than about 6.5 to greater than about 7.0 at the site of dilution. The dilution time was modified by changing the length of tubing between the mixing Tee and the point of dilution, thus modulating the residence time within acidic buffer. Percent encapsulation was quantified by the Ribogreen fluorescence assay after buffer exchange into PBS via dialysis or TFF. FIG. 4 shows a graph of percent encapsulation versus incubation time (also referred to as residence time) in the resulting acidic buffer (pH less than about 6.0) from the combination of the lipid and aqueous solutions. Encapsulation percentages of greater than 90% were achieved at 300 seconds as shown in FIG. 4.

## EXAMPLE 2

This example describes the change in surface charge of the nanoparticles associated with the altering step, which changes the pH of the suspension to a pH that is greater than the pKa of the ionizable molecule in the particles. This example shows that the surface charge of lipid nanoparticles containing ionizable lipid changed when the pH was altered to be greater than the pKa of the ionizable lipid. The magnitude of the change in surface charge was greater for lipid nanoparticles containing mRNA than for lipid nanoparticles that did not contain mRNA.

Lipid nanoparticles containing mRNA were formed as described in Example 1. Lipid nanoparticles that did not contain mRNA ("Empty") were formed by a similar process as described in Example 1 except the aqueous solution did not contain mRNA. The ionizable lipid had a pKa of 6.3. After an incubation time of at least 300 seconds, the pH of the suspension containing the mRNA and the suspension containing the empty lipid nanoparticles was altered by changing the pH of the suspension. Particles were further purified by TFF and were subsequently filtered through a sterilizing-grade membrane. The zeta potential of the lipid particles were measured at various pHs of the

resulting suspension using a Wyatt Mobius zeta-potentiometer. FIG.5 shows a graph of zeta potential versus pH for mRNA and empty lipid nanoparticles. As shown in FIG. 5, the zeta potential of the empty and mRNA lipid nanoparticles are substantially the same until the isoelectric point of the ionizable lipid. After the isoelectric point, the surface charge of the mRNA lipid nanoparticles were substantially more negative than the empty nanoparticles.

### EXAMPLE 3

This example describes the filtration properties of suspensions containing mRNA lipid nanoparticles that have a pH greater than the pKa of the ionizable lipid in the particle. When the pH of the suspension was greater than the pKa of the ionizable lipid, the filtration time was reduced, a higher permeate flux was achieved throughout the filtration process, and the coefficient in variation of the resulting particles was reduced compared to a suspension having a pH less than the pKa of the ionizable lipid (control).

Lipid nanoparticles containing mRNA were formed as described in Example 1. The pKa of the ionizable lipid was 6.3. After formation of the particles and allowing the particles to incubate for at least 300 seconds, the pH of the suspension was changed from a pH of about 5.7 to a pH of about 7.4 in an altering step. The pH was altered by volumetric addition of a 1M Tris pH 8 buffer to a final buffer composition of 100 mM Tris. The control suspension was also incubated for at least 300 second but the pH of the suspension was not altered and remained at about pH 5.7 prior to diafiltration. However, pH 5.7 buffer was added to the control to ensure that the concentration of particles were substantially the same in both suspension. For the control, the pH of the suspension was changed gradually during filtration using diafiltration. The pH was increased during the diafiltration step with each diafiltration volume (DV) and a pH of 7.0 was reached after six diafiltration volumes. The pH at two DV and four DV were 6.05 and 6.41, respectively.

Both suspensions were filtered using tangential flow filtration. The tangential flow filtration process involved a first concentration step, then a diafiltration step using six diafiltration volumes, and a second concentration step. FIG. 6A shows the permeate flux versus time for the two suspensions. The suspension having a pH of about 7.4 had a filtration time of about 50 minutes while the suspension having a pH of about 5.7 has a filtration time of about 140 minutes. The filtration time included a first concentration

step, diafiltration with 12 diafiltration volumes, and a final concentration step. The higher permeate flux achieved with the suspension having a pH of about 7.4 increased the filtration rate resulting in a lower filtration time. FIG. 6B shows the permeate flux at each stage of the tangential flow filtration for both suspensions. As shown in FIG. 6B, the permeate flux for the suspension having a pH of about 7.4 was greater than the suspension having a pH of about 5.7 during all stages of filtration. Thus, the suspension having a pH greater than the pKa of the ionizable lipid had better filtration performance than the suspension having a pH less than the pKa of the ionizable lipid.

The pH of the suspension during tangential flow filtration also influenced the average particle size, as well as polydispersity, of the filtered suspension. FIG. 7A shows the average particle size during various stages of tangential flow filtration (wherein DV stands for diafiltration volume), and after a sterile filtration for both suspensions. As shown in FIG. 7A, the average particle size of the particles in the suspension having a pH of about 7.4 was smaller than the average particle size of the particles in the suspension having a pH of about 5.7 after tangential flow filtration and sterile filtration. FIG. 7B shows the percent polydispersity for the particles during various stages of tangential flow filtration and after a sterile filtration for both suspensions. As shown in FIG. 7B, the suspension having a pH of about 7.4 had a significantly lower polydispersity in average particle size than the suspension having a pH of about 5.7. Notably, after sterile filtration, the pH 7.4 suspension had a polydispersity of less than about 3% and the pH 5.7 suspension had a polydispersity of about 20%.

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.

**CLAIMS**

What is claimed is:

5

1. A method comprising:

changing a pH of a suspension comprising particles comprising mRNA and an ionizable molecule from a first pH to a second pH, wherein the second pH is greater than a pKa of the ionizable molecule; and

10

filtering the suspension to produce a filtered suspension comprising at least a portion of the particles, wherein a coefficient of variation of a cross-sectional dimension of the particles in the filtered suspension is less than or equal to about 20%.

2. A method comprising:

15

changing a pH of a suspension comprising particles comprising mRNA and an ionizable molecule from a first pH to a second pH, wherein the second pH is greater than a pKa of the ionizable molecule; and

20

forming a composition comprising at least a portion of the particles, wherein a coefficient of variation of a cross-sectional dimension of the particles in the composition is less than or equal to about 20%.

3. A method comprising:

25

changing an average zeta potential of a plurality of particles comprising mRNA in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential; and

30

filtering the suspension to produce a filtered suspension comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the filtered suspension is greater than or equal to about 50% and less than or equal to about 99%.

4. A method comprising:

changing an average zeta potential of a plurality of particles comprising mRNA in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential; and

forming a composition comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the composition is greater than or equal to about 50% and less than or equal to about 99%.

5 5. A method comprising:

changing an average zeta potential of a plurality of particles comprising polynucleotides having greater than or equal to 50 nucleotides in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential; and

10 filtering the suspension to produce a filtered suspension comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the filtered suspension is greater than or equal to about 50% and less than or equal to about 99%.

15 6. A method comprising:

changing an average zeta potential of a plurality of particles comprising polynucleotides having greater than or equal to 50 nucleotides in a suspension from a first zeta potential to a second zeta potential, wherein the second zeta potential is less than the first zeta potential; and

20 forming a composition comprising at least a portion of the particles, wherein a weight percentage of mRNA in the particles in the composition is greater than or equal to about 50% and less than or equal to about 99%.

7. A method of filtering comprising:

25 filtering a suspension comprising particles comprising a polynucleotide and an ionizable molecule having a pKa less than the pH of the suspension,

wherein the filtration step comprises a concentration step and a diafiltration step, and wherein the permeate flux throughout the diafiltration step is greater than or equal to about 20 L/m<sup>2</sup>h when the transmembrane pressure is between about 1 psi and about 20  
30 psi.

8. A method as in any one of the preceding claims, comprising filtering the suspension to produce a filtered suspension comprising the composition.

9. A method as in any one of the preceding claims, wherein the filtering step comprises passing at least a portion of the suspension thorough a porous substrate.
- 5 10. A method as in any one of the preceding claims, wherein the filtering step comprises tangential flow filtration.
11. A method as in any one of the preceding claims, wherein the filtering step comprises passing the suspension through a filter having a mean pore size of less than or  
10 equal to about 0.2 microns after the tangential flow filtration.
12. A method as in any one of the preceding claims, comprising forming the particles comprising mRNA and the ionizable molecule.
- 15 13. A method as in any one of the preceding claims, wherein the forming step comprises exposing a first solution comprising the ionizable molecule to a second solution comprising the mRNA to form the suspension comprising the particles.
14. A method as in any one of the preceding claims, wherein the first solution  
20 comprises an organic solvent.
15. A method as in claim 9, wherein the organic solvent is an alcohol.
16. A method as in any one of the preceding claims, wherein the second solution  
25 comprises an aqueous solution comprising a buffer.
17. A method as in any one of the preceding claims, wherein the pH of the suspension prior to the changing step is less than or equal to about the pKa of the ionizable molecule.  
30
18. A method as in any one of the preceding claims, wherein the pKa of ionizable molecule is greater than or equal to about 6.



19. A method as in any one of the preceding claims, wherein the pKa of the ionizable molecule is between about 6 and 7.
20. A method as in any one of the preceding claims, wherein the pKa of the ionizable molecule is about 6.2.
21. A method as in claim 8, wherein the pH of the first solution is less than or equal to about pH 6.
22. A method as in claim 8 or 16, wherein the pH of the second solution is greater than about pH 6.
23. A method as in any one of the preceding claims, wherein the permeate flux throughout the diafiltration step is less than or equal to about 120 L/m<sup>2</sup>h when the transmembrane pressure is between about 1 psi and about 20 psi, or between about 10 psi and about 15 psi.
24. A method as in any one of the preceding claims, comprising incubating the ionizable molecule and the mRNA in the suspension for greater than or equal to about 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes.
25. A method as in any one of the preceding claims, wherein the encapsulation efficiency after the incubation step is greater than or equal to about 70%, 80%, or 90%.
26. A method as in any one of the preceding claims, wherein the ionizable molecule comprises a nitrogen.
27. A method as in any one of the preceding claims, wherein the ionizable molecule is a cationic lipid.
28. A method as in any one of the preceding claims, wherein the cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-

dioxolane, dilinoleyl-methyl-4-dimethylaminobutyrate, and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

29. A method as in any one of the preceding claims, wherein the particle comprises a sterol molecule; optionally, wherein the sterol molecule is a cholesterol molecule.

30. A method as in any one of the preceding claims, wherein the particles in the filtered suspension have an average cross-sectional dimension less than or equal to about 150 nm, about 120 nm, or about 100 nm.

31. A method as in any one of the preceding claims, wherein the particles in the suspension have a first zeta potential and the particles in the filtered suspension have a second zeta potential, and wherein the second zeta potential is less than the first zeta potential.

32. A method as in any one of the preceding claims, wherein the first zeta potential is greater than or equal to about 0 mV.

33. A method as in any one of the preceding claims, wherein a coefficient of variation of a cross-sectional dimension of the particles in the filtered suspension is less than or equal to about 20%, about 15%, or about 10%.

34. A method as in any one of the preceding claims, wherein the polynucleotides are mRNA molecules.

35. A method as in any one of the preceding claims, wherein the cross-sectional dimension of the particles is a largest cross-sectional dimension of the particles.

36. A composition comprising:  
a plurality of particles comprising mRNA, wherein:  
an average cross-sectional dimension of the particles in the composition is less than or equal to about 150 nm,

a coefficient of variation of a cross-sectional dimension of the particles in the composition is less than or equal to about 20%, and

a weight percentage of mRNA in the particles is greater than or equal to about 50% and less than or equal to about 99%.

5

37. A composition as in any one of the preceding claims, wherein the particles further comprises an ionizable molecule.

38. A composition as in any one of the preceding claims, wherein the ionizable molecule comprises a nitrogen.

10

39. A composition as in any one of the preceding claims, wherein the ionizable molecule is a cationic lipid.

40. A composition as in any one of the preceding claims, wherein the cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane, dilinoleyl-methyl-4-dimethylaminobutyrate, and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

15

41. A composition as in any one of the preceding claims, wherein the particle comprises a sterol molecule; optionally, wherein the sterol molecule is a cholesterol molecule.

20

42. A composition as in any one of the preceding claims, wherein the particles have a zeta potential of less than or equal to about -1 mV.

25

43. A composition as in any one of the preceding claims, wherein the pKa of ionizable molecule is greater than or equal to about 6.

44. A composition as in any one of the preceding claims, wherein a coefficient of variation of a cross-sectional dimension of the particles in the filtered suspension is less than or equal to about 15%.

30




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B






FIG. 7A




FIG. 7B

## INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/US2016/047406**

A. CLASSIFICATION OF SUBJECT MATTER <b>A61K 9/127 (2006.01) A61K 48/00 (2006.01)</b>		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Espacenet, google: Moderna therapeutics liposome mRNA  CAPLUS, MEDLINE, BIOSIS, EMBASE, EPODOC, WPIAP: lower zeta potential, raise pH, cationic lipid, pka, liposome, mRNA, filter, and like terms. CPC marks queried: A61K9/127, A61K9/1272, A61K9/1278, A61K48/0091, A61K48/0008/LOW		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 31 October 2016	Date of mailing of the international search report 31 October 2016	
Name and mailing address of the ISA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au	Authorised officer  Felix White AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. +61262832565	

<b>INTERNATIONAL SEARCH REPORT</b>		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		<b>PCT/US2016/047406</b>
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US 2012/0021042 A1 (PANZNER et al) 26 January 2012 [0188], [0190], [0199], [0346], Tables 8, 10, 12 as above	1-27, 29-39, 41-44 28, 40
X Y	WO 2014/071379 A1 (PRONAI THERAPEUTICS, INC.) 08 May 2014 [00450] et seq as above	1-27, 29-39, 41-44 28, 40
Y	WO 2014/204728 A1 (THE BROAD INSTITUTE et al) 24 December 2014 [00420] et seq	28, 40
A	ANDREAKOS, E. et al, "Amphoteric Liposome Enable Systemic Antigen-Presenting Cell-Directed Delivery of CD40 Antisense and are Therapeutically Effective in Experimental Arthritis" Arthritis & Rheumatism, 2009, vol. 60, pps 994-1005 Results 1st paragraph (p. 996)	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/047406

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 2012/0021042 A1	26 January 2012	US 2012021042 A1	26 Jan 2012
		AU 2005300638 A1	11 May 2006
		AU 2005306075 A1	26 May 2006
		AU 2006291429 A1	22 Mar 2007
		AU 2006291429 B2	04 Apr 2013
		AU 2007306556 A1	17 Apr 2008
		AU 2007306556 B2	10 Apr 2014
		AU 2008309880 A1	16 Apr 2009
		AU 2008309880 B2	10 Jul 2014
		AU 2014203387 A1	10 Jul 2014
		AU 2014203387 B2	07 Jul 2016
		CA 2586708 A1	11 May 2006
		CA 2587337 A1	26 May 2006
		CA 2622584 A1	22 Mar 2007
		CA 2665783 A1	17 Apr 2008
		CA 2702103 A1	16 Apr 2009
		CA 2889540 A1	22 Mar 2007
		DE 102004054731 A1	23 Nov 2006
		DE 102004056659 A1	01 Jun 2006
		DE 102006054192 A1	20 Sep 2007
		EP 1658839 A1	24 May 2006
		EP 1764089 A1	21 Mar 2007
		EP 1764090 A1	21 Mar 2007
		EP 1764091 A2	21 Mar 2007
		EP 1807050 A1	18 Jul 2007
		EP 1811960 A2	01 Aug 2007
		EP 1911443 A1	16 Apr 2008
		EP 2004141 A2	24 Dec 2008
		EP 2094238 A2	02 Sep 2009
		EP 2211840 A2	04 Aug 2010
		EP 2462924 A2	13 Jun 2012
		JP 2010505899 A	25 Feb 2010
		JP 5424885 B2	26 Feb 2014
		JP 2009507876 A	26 Feb 2009
		JP 5571308 B2	13 Aug 2014
		JP 2011500520 A	06 Jan 2011

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2016/047406**

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<b>Patent Document/s Cited in Search Report</b>		<b>Patent Family Member/s</b>	
<b>Publication Number</b>	<b>Publication Date</b>	<b>Publication Number</b>	<b>Publication Date</b>
		JP 5711535 B2	07 May 2015
		JP 2008518998 A	05 Jun 2008
		JP 2008520600 A	19 Jun 2008
		JP 2015110625 A	18 Jun 2015
		KR 20080082956 A	12 Sep 2008
		US 2011076322 A1	31 Mar 2011
		US 9066867 B2	30 Jun 2015
		US 2012135065 A1	31 May 2012
		US 9283186 B2	15 Mar 2016
		US 2006159737 A1	20 Jul 2006
		US 2006216343 A1	28 Sep 2006
		US 2007104775 A1	10 May 2007
		US 2008088046 A1	17 Apr 2008
		US 2008089932 A1	17 Apr 2008
		US 2010330154 A1	30 Dec 2010
		US 2014056970 A1	27 Feb 2014
		US 2014178462 A1	26 Jun 2014
		US 2015231073 A1	20 Aug 2015
		US 2016151282 A1	02 Jun 2016
		WO 2006048329 A1	11 May 2006
		WO 2006053646 A2	26 May 2006
		WO 2007031333 A2	22 Mar 2007
		WO 2007107304 A2	27 Sep 2007
		WO 2008043575 A2	17 Apr 2008
		WO 2009047006 A2	16 Apr 2009

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/047406

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2014/071379 A1	08 May 2014	WO 2014071379 A1	08 May 2014
		CA 2890875 A1	08 May 2014
		CN 104903450 A	09 Sep 2015
		EP 2914722 A1	09 Sep 2015
		HK 1214628 A1	29 Jul 2016
		JP 2015536952 A	24 Dec 2015
		KR 20150086294 A	27 Jul 2015
		US 2015272980 A1	01 Oct 2015
		WO 2014/204728 A1	24 December 2014
AU 2013359123 A1	30 Jul 2015		
AU 2013359123 B2	14 Jul 2016		
AU 2013359199 A1	30 Jul 2015		
AU 2013359212 A1	30 Jul 2015		
AU 2013359238 A1	30 Jul 2015		
AU 2013359238 B2	14 Jul 2016		
AU 2013359262 A1	30 Jul 2015		
AU 2014281026 A1	28 Jan 2016		
AU 2014281027 A1	28 Jan 2016		
AU 2014281028 A1	28 Jan 2016		
AU 2014281031 A1	21 Jan 2016		
CA 2894668 A1	19 Jun 2014		
CA 2894681 A1	19 Jun 2014		
CA 2894684 A1	19 Jun 2014		
CA 2894688 A1	19 Jun 2014		
CA 2894701 A1	19 Jun 2014		
CA 2915795 A1	24 Dec 2014		
CA 2915834 A1	24 Dec 2014		
CA 2915837 A1	24 Dec 2014		
CA 2915842 A1	24 Dec 2014		
CA 2915845 A1	24 Dec 2014		
CN 105121648 A	02 Dec 2015		
CN 105164264 A	16 Dec 2015		
CN 105209621 A	30 Dec 2015		
CN 105492611 A	13 Apr 2016		
CN 105658796 A	08 Jun 2016		

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/047406

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		CN 105683379 A	15 Jun 2016
		CN 105793425 A	20 Jul 2016
		EP 2764103 A2	13 Aug 2014
		EP 2764103 B1	19 Aug 2015
		EP 2771468 A1	03 Sep 2014
		EP 2771468 B1	11 Feb 2015
		EP 2784162 A1	01 Oct 2014
		EP 2784162 B1	08 Apr 2015
		EP 2825654 A1	21 Jan 2015
		EP 2840140 A1	25 Feb 2015
		EP 2848690 A1	18 Mar 2015
		EP 2896697 A1	22 Jul 2015
		EP 2896697 B1	02 Sep 2015
		EP 2898075 A1	29 Jul 2015
		EP 2898075 B1	09 Mar 2016
		EP 2921557 A1	23 Sep 2015
		EP 2921557 B1	13 Jul 2016
		EP 2931892 A1	21 Oct 2015
		EP 2931897 A2	21 Oct 2015
		EP 2931898 A2	21 Oct 2015
		EP 2931898 B1	09 Mar 2016
		EP 2931899 A1	21 Oct 2015
		EP 2932421 A1	21 Oct 2015
		EP 2940140 A1	04 Nov 2015
		EP 2998400 A1	23 Mar 2016
		EP 3011029 A1	27 Apr 2016
		EP 3011030 A1	27 Apr 2016
		EP 3011031 A1	27 Apr 2016
		EP 3011032 A1	27 Apr 2016
		EP 3011033 A1	27 Apr 2016
		EP 3011034 A1	27 Apr 2016
		EP 3011035 A1	27 Apr 2016
		EP 3031921 A1	15 Jun 2016
		EP 3045537 A1	20 Jul 2016
		EP 3064585 A1	07 Sep 2016
		HK 1201290 A1	28 Aug 2015

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/047406

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		HK 1202586 A1	02 Oct 2015
		HK 1206388 A1	08 Jan 2016
		HK 1207119 A1	22 Jan 2016
		HK 1208045 A1	19 Feb 2016
		HK 1208056 A1	19 Feb 2016
		HK 1209153 A1	24 Mar 2016
		HK 1209154 A1	24 Mar 2016
		HK 1210221 A1	15 Apr 2016
		HK 1215048 A1	12 Aug 2016
		JP 2016093196 A	26 May 2016
		JP 2016129516 A	21 Jul 2016
		JP 2016165307 A	15 Sep 2016
		JP 2016171817 A	29 Sep 2016
		JP 2016500262 A	12 Jan 2016
		JP 2016501531 A	21 Jan 2016
		JP 2016501532 A	21 Jan 2016
		JP 2016504026 A	12 Feb 2016
		JP 2016505256 A	25 Feb 2016
		JP 2016521993 A	28 Jul 2016
		JP 2016521994 A	28 Jul 2016
		JP 2016521995 A	28 Jul 2016
		JP 2016523082 A	08 Aug 2016
		JP 2016524472 A	18 Aug 2016
		KR 20150105633 A	17 Sep 2015
		KR 20150105634 A	17 Sep 2015
		KR 20150105635 A	17 Sep 2015
		KR 20150105956 A	18 Sep 2015
		KR 20150107739 A	23 Sep 2015
		KR 20160019553 A	19 Feb 2016
		KR 20160030187 A	16 Mar 2016
		KR 20160034901 A	30 Mar 2016
		KR 20160044457 A	25 Apr 2016
		KR 20160056869 A	20 May 2016
		SG 11201504519T A	30 Jul 2015
		SG 11201504523U A	30 Jul 2015
		SG 11201510284X A	28 Jan 2016

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/047406

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		SG 11201510286Q A	28 Jan 2016
		SG 11201510327T A	28 Jan 2016
		US 8697359 B1	15 Apr 2014
		US 2014170753 A1	19 Jun 2014
		US 8771945 B1	08 Jul 2014
		US 2014179006 A1	26 Jun 2014
		US 8795965 B2	05 Aug 2014
		US 2014242700 A1	28 Aug 2014
		US 8865406 B2	21 Oct 2014
		US 2014273231 A1	18 Sep 2014
		US 8871445 B2	28 Oct 2014
		US 2014234972 A1	21 Aug 2014
		US 8889356 B2	18 Nov 2014
		US 2014273234 A1	18 Sep 2014
		US 8889418 B2	18 Nov 2014
		US 2014335620 A1	13 Nov 2014
		US 8895308 B1	25 Nov 2014
		US 2014273232 A1	18 Sep 2014
		US 8906616 B2	09 Dec 2014
		US 2014248702 A1	04 Sep 2014
		US 8932814 B2	13 Jan 2015
		US 2014227787 A1	14 Aug 2014
		US 8945839 B2	03 Feb 2015
		US 2014186958 A1	03 Jul 2014
		US 8993233 B2	31 Mar 2015
		US 2014256046 A1	11 Sep 2014
		US 8999641 B2	07 Apr 2015
		US 2014179770 A1	26 Jun 2014
		US 2014186843 A1	03 Jul 2014
		US 2014186919 A1	03 Jul 2014
		US 2014189896 A1	03 Jul 2014
		US 2014242664 A1	28 Aug 2014
		US 2014242699 A1	28 Aug 2014
		US 2014310830 A1	16 Oct 2014
		US 2014357530 A1	04 Dec 2014
		US 2015020223 A1	15 Jan 2015

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/047406

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 2015031134 A1	29 Jan 2015
		US 2015079681 A1	19 Mar 2015
		US 2015184139 A1	02 Jul 2015
		US 2015203872 A1	23 Jul 2015
		US 2015232882 A1	20 Aug 2015
		US 2015247150 A1	03 Sep 2015
		US 2015291965 A1	15 Oct 2015
		US 2015356239 A1	10 Dec 2015
		US 2016115488 A1	28 Apr 2016
		US 2016115489 A1	28 Apr 2016
		US 2016153004 A1	02 Jun 2016
		US 2016153005 A1	02 Jun 2016
		US 2016153006 A1	02 Jun 2016
		US 2016168594 A1	16 Jun 2016
		US 2016175462 A1	23 Jun 2016
		US 2016186213 A1	30 Jun 2016
		US 2016272965 A1	22 Sep 2016
		US 2016281072 A1	29 Sep 2016
		WO 2014093595 A1	19 Jun 2014
		WO 2014093622 A2	19 Jun 2014
		WO 2014093635 A1	19 Jun 2014
		WO 2014093655 A2	19 Jun 2014
		WO 2014093661 A2	19 Jun 2014
		WO 2014093694 A1	19 Jun 2014
		WO 2014093701 A1	19 Jun 2014
		WO 2014093709 A1	19 Jun 2014
		WO 2014093712 A1	19 Jun 2014
		WO 2014093718 A1	19 Jun 2014
		WO 2014204723 A1	24 Dec 2014
		WO 2014204724 A1	24 Dec 2014
		WO 2014204725 A1	24 Dec 2014
		WO 2014204726 A1	24 Dec 2014
		WO 2014204727 A1	24 Dec 2014
		WO 2014204729 A1	24 Dec 2014

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

<b>INTERNATIONAL SEARCH REPORT</b>		International application No.	
Information on patent family members		<b>PCT/US2016/047406</b>	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
<b>Patent Document/s Cited in Search Report</b>		<b>Patent Family Member/s</b>	
<b>Publication Number</b>	<b>Publication Date</b>	<b>Publication Number</b>	<b>Publication Date</b>
<b>End of Annex</b>			

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.